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ABSTRACT 
 Alzheimer’s disease (AD) is the most common cause of dementia in the aging 
population. As the disease progresses, AD leads to cognitive deficits affecting memory, 
changes in personality, and language dysfunction. AD is characterized by the pathological 
extracellular accumulation of fibril β-amyloid (Aβ) into senile plaques and the 
intraneuronal accumulation of the microtubule-associated protein tau as neurofibrillary 
tangles. Initially, insoluble fibrillary Aβ was believed to be central to disease pathogenesis, 
but more recent evidence implicates soluble oligomeric Aβ as the trigger behind the 
earliest cognitive deficits in AD. Under normal conditions, Aβ at low, physiological levels 
(pM) functions as a positive neuromodulator, enhancing synaptic plasticity and function.  
In addition, mouse models lacking Aβ show deficits in cognitive function and loss of 
synapses, suggesting, therefore, a vital role of Aβ in the maintenance of synaptic activity.  
On the other hand, pathological levels of Aβ (high nM-μM) cause irreversible 
degeneration of neuronal processes and the loss of synaptic function and connections in 
select areas of the brain.  Previously, we reported that an endogenous N-terminal 
fragment derived from full-length Aβ retains the latter’s positive neuromodulatory activity 
and, notably, protects against Aβ-induced synaptic and memory deficits. Furthermore, 
through subsequent mutational analysis, we found a core sequence (YEVHHQ: N-
Aβcore) within the N-terminal fragment accounting for its activity.  Here, we aimed to 
characterize the neuroprotective potential of the N-Aβcore against Aβ-induced neuronal 
and synaptic damage, while elucidating the neuroprotective mechanism(s) of the N-
Aβcore.  
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 Utilizing a neuronal toxicity model (rodent hybrid neuroblastoma cells transfected 
with α4β2 nicotinic acetylcholine receptors, nAChRs), the N-Aβcore was shown to retain 
receptor-linked activity. Subsequent mutational analysis demonstrated that the two 
histidine residues, and to a lesser degree, the tyrosine residue in the N-Aβcore are 
essential for this activity.  In comparison to the sustained-elevated Ca2+ response elicited 
by Aβ, the N-Aβcore and N-terminal fragment displayed differential Ca2+ responses, 
suggesting the activation of an alternative, Aβ-independent pathway. In addition, the N-
Aβcore was shown to be neuroprotective against Aβ-induced oxidative stress, ER stress, 
mitochondrial dysregulation, apoptosis, and synaptic dysfunction.   
We have also previously reported an increase in activity of various mitogen-
activated protein kinases (MAPKs) in response to prolonged, sustained Aβ exposure.   We 
therefore addressed whether the N-Aβcore has an impact on Aβ-linked MAPK activation. 
In our neuronal toxicity model, the N-Aβcore reduced the Aβ-induced MAPK activity.  
Interestingly, preliminary evidence indicates that low levels (pM) of the N-Aβcore nearly 
abolished c-Jun N-terminal kinase (JNK) activity.  Furthermore, low levels of the N-Aβcore 
showed an increase in cAMP response element-binding protein (CREB) activity and 
expression, which has been shown to be downregulated in AD and AD models. Taken 
together, these findings suggest that the N-Aβcore is neuroprotective against Aβ-induced 
neuronal and synaptic toxicity by partially inhibiting Aβ binding to target receptors and 
subsequently activating an Aβ-independent neuroprotective pathway.
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CHAPTER 1: INTRODUCTION 
 
1.1 Alzheimer Disease 
Alzheimer’s disease (AD) is a neurodegenerative disease, currently incurable, which 
presents one of the largest unmet needs in medicine [1, 2]. AD is characterized by the 
accumulation of intracellular neurofibrillary tangles composed of hyperphosphorylated tau 
and extracellular amyloid beta (Aβ) deposits evident as senile plaques [3]. With the 
progression of these pathological hallmarks, neuronal loss in select regions of the brain 
parallel the clinical symptom of progressive and gradual decline in cognitive function.  
There are a number of existing hypotheses that have been proposed to explain the 
origins of AD, but the amyloid cascade hypothesis, while controversial, has been the most 
influential theory for research and drug development to date, suggesting that the 
formation, aggregation and deposition of Aβ peptides are primary events in AD 
pathogenesis [4–6]. This hypothesis gained ground when several key studies revealed 
that accumulation of soluble, oligomeric Aβ preceded accumulation of 
hyperphosphorylated tau, with the former being relatively specific for AD independent of 
plaque formation, and the latter being found in other disorders. More importantly, 
subsequent studies indicated that oligomeric Aβ may foster tau hyperphosphorylation in 
AD, with intracellular hyperphosphorylated tau being the primary driver of neuronal 
toxicity and, ultimately, neurodegeneration [7–9]. In addition, the discovery that AD could 
be inherited in an autosomal dominant fashion [10–12] further strengthened the amyloid 
cascade hypothesis claim. The autosomal mutations reside in genes coding for the 
amyloid precursor protein (APP), an integral type-1 transmembrane protein that is 
 2 
sequentially cleaved by specific processing enzymes, known as secretases, or in genes 
coding for key components of one of secretases, namely presenilin 1 (PSEN1) [12] or 
PSEN2 [13] in the γ-secretase complex [14]. Cleavage by the β- and γ-secretases yields 
Aβ, while cleavage by α-secretase and γ-secretase (and/or β-secretase) is 
nonamyloidogenic [15–17]. Lastly, the most prominent genetic risk factor for late-onset 
AD, ApoE-ε4, was recently shown to drive amyloid pathology at the earliest (seeding) 
stage [18, 19]. 
 In considering alternative models for the origin of the disease, it has been argued 
that extant evidence does not fully explain or fit easily with the simplest version of the 
amyloid hypothesis. One of the main objections to the hypothesis is that the amyloid load 
in the brain does not invariably correlate with the degree of cognitive impairments in 
patients, as PET imaging have revealed substantial amyloid burden (as aggregates or 
plaques) in a subset of individuals that do not manifest clinical symptoms. Moreover, 
treatments (e.g., immunization) that reduced amyloid burden did not lead to clinical 
improvement. Finally, neurodegeneration correlates best with neurofibrillary tangle 
burden. However, there remains a considerable body of evidence demonstrating that 
soluble Aβ oligomers, not monomers or insoluble fibrils or plaques, are responsible for 
synaptic dysfunction, neuronal damage and memory deficits exhibited in AD [20–22].    
 The overproduction and self-association of Aβ monomers into soluble oligomers 
and/or inadequate clearance of Aβ [23] leads to their accumulation, which increases 
oxidative stress [24], elicits mitochondrial dysfunction [25, 26], elevates presynaptic 
calcium [27], causes synaptic dysfunction [28, 29] and synaptic loss [30], and ultimately 
neuronal death [31] (Fig. 1).  On the other hand, physiological levels of Aβ in healthy 
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normal brains have been found to enhance synaptic plasticity [32, 33], synaptic function 
[34–36] and fear memory [32], suggesting that Aβ acts as a positive neuromodulator at 
low concentrations (pM range). The prominent role Aβ plays in AD pathology makes it a 
reasonable target for therapeutic intervention(s), and the majority of drug research and 
development to date has been centered around the amyloid cascade hypothesis, aiming 
to reduce Aβ formation and aggregation, inhibiting Aβ toxicity and/or increasing Aβ 
clearance.  
 1.2 Amyloid Precursor Protein (APP) Processing  
 
Figure 1: Aβ Toxicity 
Accumulation of soluble Aβ oligomers leads to Ca2+ dysregulation and dysfunction, 
mitochondrial dysfunction, oxidative stress, hyperphosphorylation of tau, proteasome disruption 
and synaptic deficits. (Figure adapted from [31])  
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The amyloid precursor protein (APP) is a single-spanning transmembrane protein 
that is abundantly expressed in the brain and located on chromosome 21 [37] with three 
major isoforms arising from alternative splicing [11].  APP belongs to a protein family that 
consists of APP-like protein 1 (APLP1) and 2 (APLP2) in mammals [38, 39], but the Aβ 
domain is unique to APP.  Unfortunately, the function of APP is still not widely understood, 
but it has been suggested to be involved in neurite outgrowth and synaptogenesis [40, 
41], neuronal protein trafficking [42], transmembrane receptor signaling [43, 44], calcium 
signaling [45], cellular and synaptic adhesion [46] and synaptic and neuro-protection  [40, 
47–49].  More importantly, APP has gained notoriety from its central role in Aβ production 
and AD pathology. 
APP is produced in large quantities in neurons and is delivered to the axon where 
it is then transported to the synaptic terminals [50].  It undergoes regulated sequential 
cleavage of either α- (nonamyloidogenic pathway) or β- (amyloidogenic pathway) 
secretase followed by γ-secretase.  The nonamyloidogenic pathway involves the 
cleavage of APP within the Aβ domain by an α-secretase, releasing a soluble ectodomain 
of APP called sAPPα.  Studies have shown sAPPα play a critical role in neuronal plasticity 
and survival, and be protective against excitotoxicity [51, 52].  sAPPα also regulates 
neural stem cell proliferation and is important for early central nervous system (CNS) 
development [53, 54].  Interestingly, sAPPα has also been shown to be able to rescue 
APP deficient mice abnormalities [55], suggesting that most of the physiological role of 
APP is mediated by sAPPα.  After α-cleavage (CTFα), the carboxy terminal fragment of 
APP remains in the membrane and is further cleaved by γ-secretase, releasing a P3 
fragment, which is rapidly degraded and is believed to be of no importance, and an APP 
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intracellular domain (AICD).  The AICD is believed to regulate the transcription of 
neprilysin (an Aβ degradation enzyme), BACE1 (a β-secretase) and APP [56, 57].        
In a mutually exclusive pathway, the production of Aβ is through the sequential 
enzymatic cleavage via the β- and γ-secretases [58] (Fig. 2).  BACE1, the major β-
secretase involved in APP metabolism, is a transmembrane aspartic protease that 
cleaves at the β-sites of Aβ (Asp1 and Glu11), releasing an sAPPβ ectodomain.   The 
CTFβ is cleaved by γ-secretase at one of several sites varying from +40 to +44 to 
generate various Aβ peptides.  As Aβ is partially derived from the transmembrane (TM) 
domain of APP, the peptide has a C-terminal hydrophobic domain, which has been shown 
to largely but not exclusively account for its aggregation and neurotoxicity [59, 60].  
 
1.2.1 The N-Aβ fragment (Aβ1-15) 
In contrast, a larger hydrophilic domain resides on the N-terminal side of the 
peptide. It has been shown that a 15-16 amino acid N-terminal Aβ fragment (N-Aβ 
fragment) can be produced from this domain via an alternative α-secretase-linked 
pathway and is present at significant levels in cerebrospinal fluid (CSF) [15] (Fig. 2).  Due 
to its hydrophilicity, the N-Aβ fragment does not form oligomers and is non-toxic [61].  
Moreover, pM-nM concentrations of the N-Aβ fragment are approximately twice as 
effective as Aβ in stimulating receptor-linked increases in Ca2+, enhancing long-term 
potentiation (LTP) and enhancing contextual fear conditioning (CFC)[62].   
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1.2.2 The N-Aβcore (Aβ10-15) 
The N-Aβcore is not endogenously produced (Fig. 2) but is believed to be the 
responsible core sequence for Aβ’s and the N-Aβ fragment’s receptor-linked Ca2+ 
responses [62] and thus potentially accounting for the neuromodulatory activity of Aβ.  
The small size and non-toxic nature of the N-Aβcore makes it an ideal scaffold for 
therapeutic exploration and development.  
 
1.3 Current Therapeutic Strategies Specific to Aβ Toxicity      
There are three main intervention strategies for therapy aimed at Aβ: reducing Aβ 
production, facilitating Aβ clearance, and preventing Aβ aggregation. 
     Reducing Aβ production through inhibiting the activities of γ-secretase or β-secretase 
has been shown to reduce the levels of plasma, brain and CSF Aβ in multiple models 
overexpressing APP [63–68].  Although able to reduce Aβ, the γ-secretase inhibitors 
cause drug-related toxicities in the gastrointestinal tract [69], thymus [70] and spleen [65, 
71]. As for β-secretase, small-molecules capable of penetrating the blood brain barrier 
(BBB) while potently inhibiting the enzyme in view of its large active site are under 
Figure 2: APP Processing 
APP is a transmembrane spanning protein.  The production of Aβ is through the sequential 
cleavage of β- and γ- secretase giving rise to varying lengths of Aβ.  The N-terminal Aβ fragment 
(shown in blue) is produced through a lesser known alternative pathway with cleavage by the 
β- and α- secretase.  The lysine residue is cleaved off by a C-terminal carboxypeptidase, thus 
producing a 15aa fragment.  The N-Aβcore (shown in green) is not produced endogenously.  
 
 7 
development.  On the other hand, vaccine-targeting or passive immunotherapy to lower 
Aβ has proven effective [72, 73] but without any clinical significant improvement and, 
worse, runs the risk of inflammatory - microhemorrhagic responses.  
      Interventions focused on the clearance of Aβ have been aimed at stimulating Aβ 
degradation [74–76], export of Aβ across the BBB [77–79], or removing peripheral Aβ 
[80].  Many of these drugs have been substantiated in animal models and are undergoing 
extensive clinical trials in humans, but have all failed to meet their primary clinical 
endpoints, namely improvement in memory and cognitive tasks.      
     Inhibition of Aβ aggregation has been attempted through the development of small-
molecules interacting with Aβ during oligomerization into fibrillar forms [81], but also 
without clinical success. 
 Although much progress has been made in our understanding of AD 
pathophysiology, a large number of molecules developed for therapeutic application have 
fallen short in clinical trials.  Therefore, a new therapeutic agent that not only alleviates 
the symptoms but also protects against further neuronal damage is greatly needed. Next, 
we will focus on the current array of neuroprotective agents reported to have identified 
activities against Aβ-induced neurotoxicity at various levels and will assess their 
therapeutic potential 
 
1.3.1 Neuroprotection 
Neuroprotection may result from endogenous factors or exogenous interventions 
mitigating metabolic, physiological or physical insult or damage in the nervous system at 
the cellular or subcellular level, potentially slowing or stopping the progression of an 
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underlying condition (e.g., stroke) or disease (e.g., AD) [82]. Agents that claim to have 
neuroprotective properties aim to prevent or slow down disease progression by slowing 
down, halting or reversing synaptic and/or neuronal dysfunction and/or loss as a means 
to preserve neuronal population survival. Many of the current neuroprotective treatments 
for neurodegeneration facilitate the reduction of oxidative stress through the application 
of antioxidants [83–87] and the block of excitotoxicity through glutamate antagonists [88–
92].  Neuroprotective strategies specific for Aβ toxicity have likewise been focused on 
targeting Aβ-induced oxidative stress [86, 93] and excitotoxicity [94, 95]. Additional 
neuroprotective strategies include blocking Aβ interactions with high affinity targets [96, 
97], down-regulating stress kinase signaling cascades [98, 99], blocking activation of 
caspases [100] and upregulating anti-apoptotic pathways [101–105].  Here, we will take 
a closer look at the most common, targeted neuroprotective strategies against Aβ toxicity. 
 
 
1.3.2 Reducing Oxidative Stress 
Oxidative stress is defined as an imbalance between reactive oxygen species 
(ROS) and their removal by the antioxidant system by either an overproduction of ROS 
or a reduction in antioxidant activity [106, 107].  Oxidative stress arises in the early stages 
of AD [108, 109] and progresses with age [110].  Oxidative stress has been shown to 
correlate with increased Aβ deposition in the brain [111, 112], increased apoptosis 
through activation of stress signals and caspases [113, 114], and promotion of Aβ 
production through β- and γ-secretase activity [115, 116].  The addition of vitamin E has 
been shown to inhibit Aβ toxicity, protein oxidation, and stress kinases in vitro [114, 117], 
with reports of lowering risk for AD in humans [117, 118], though its efficacy has been 
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controversial.  In addition, N-acetylcysteine (NAC), a potent antioxidant, may also protect 
against Aβ toxicity through induction of anti-apoptotic signaling pathways [119].  Although 
oxidative stress is a well-established pathology of AD, the use of antioxidants as 
neuroprotective therapeutics has yielded conflicting results, with no clear, direct link 
between the administration of vitamin E or NAC and AD incidence.     
 
1.3.3 Preventing Excitotoxicity 
Proper functioning of NMDA (N-methyl-D-aspartate) receptors is important for 
synaptogenesis, synaptic remodeling, and plasticity [120].  Aβ has been implicated in 
triggering excitotoxicity in AD through sustained activation of NMDA and AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid) -type glutamate receptors causing 
excessive intraneuronal Ca2+ levels due to excess glutamate resulting from oxidative 
stress and Aβ accumulation [121, 122]. Additionally, excess Aβ enhances sensitivity to 
glutamate-induced excitotoxicity [123, 124] by inhibiting glutamate re-uptake [125, 126]. 
Current therapies to protect against Aβ-induced excitotoxicity include melatonin [127], Aβ 
monomers [128] and memantine [95].  The hormone melatonin is a free radical 
scavenger, reducing oxidative stress by removing singlet oxygen, superoxide anion 
radical, hydroperoxide, hydroxyl radical and the lipid peroxide radical [129].   Memantine 
is an NMDA channel antagonist, currently, as noted, in clinical use, that blocks the 
opening of the channel without inhibiting the physiological activation needed for LTP. 
Although modulating NMDA receptors to reduce glutamate-induced excitotoxicity by 
memantine improves patient behavior, cognition and function [130], it appears that 
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memantine largely alleviates symptoms without actually providing long-term protection 
against the underlying mechanistic cause of disease. 
 
1.3.4 Modulating Stress-Activated Kinases  
Stress-activated protein kinases (SAPKs) are a family of serine/threonine kinases 
involved in a variety of cellular responses, including cell proliferation and death.  
Activation of the c-Jun N-terminal kinases (JNKs) is associated with apoptosis [131, 132], 
while the inhibition of the JNK pathway may provide protection against neuronal death 
[133, 134].  Furthermore, prolonged sustained exposure to Aβ accumulation has been 
linked to JNK activation [113, 135, 136], which has, in turn, been associated with 
degenerating neurons in AD brains [135, 137].  Inhibiting the JNK pathway has become 
a strategic avenue to prevent apoptosis [138, 139], and a few JNK inhibitors/ modulators 
have entered clinical trials [98, 100, 140] but none for AD treatment.  Although an 
attractive potential target to treating AD, inhibiting JNK activation (or any of the other 
SAPKs) systemically would likely have widespread adverse effects.  
 
1.3.5 Neuroprotection by Blocking Aβ Targets 
Aβ has been shown to interact with various receptor targets [141] to induce 
synaptic and neuronal dysfunction and death, the latter notably involving cellular prion 
protein (PrPc) [142] coupled to the metabotropic glutamate receptor 5 (mGluR5) [143], 
NMDA (and perhaps AMPA) receptors [144, 145] and nicotinic acetylcholine receptors 
(nAChRs) [61, 146](Fig. 3). The complement of receptors involved in Aβ-linked synaptic 
dysfunction, while partially overlapping with those connected to neuronal loss, appears to 
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involve a different array of targets with distinct temporal and spatial constraints whether 
the impact is on plasticity or synapse structure (i.e. dendritic spine morphology). While 
the development of compounds that can block Aβ interaction to various targets have been 
extensively explored, Aβ toxicity appears to be mediated by combined activation of Aβ 
targets, and thus identifying one agent that can prevent Aβ binding to all of the receptors 
has been challenging.  Furthermore, compounds binding to these receptors and proteins 
may also affect their normal physiological functions.   
 In addition to competitive antagonism of Aβ to protect against neuronal toxicity, a 
number of receptor-based neuroprotective pathways have been identified and utilized as 
a potential strategy independent of Aβ.  In AD models, the cyclic AMP response element 
binding protein (CREB), a constitutively expressed nuclear transcription factor that 
regulates neuronal survival and function, has been shown to be downregulated in 
hippocampal neurons [105]. It has been shown that CREB is important in neurotrophin-
mediated signaling to neuronal survival [101] and neuroprotection via upregulation of Bcl-
2 (B-cell lymphoma 2) transcription [147].  Contributing to a feed-forward mechanism, 
CREB is believed to upregulate neurotrophin expression and activity, importantly the 
brain-derived neurotrophic factor (BDNF) which is important in modulating synaptic 
plasticity [148] and a neurotrophin target receptor, the tropomyosin receptor kinase 
receptor B (TrkB) [149].  The use of neurotrophins, such as nerve growth factor (NGF) or 
BDNF, is an attractive alternative strategy for neuroprotection against Aβ toxicity, but to 
date, neurotrophins used for AD treatment have not been successful. Nonetheless, this 
approach remains promising. 
 12 
 A newly developed avenue has focused on Aβ itself to modulate endogenous 
regulatory activity rather than simply lowering Aβ levels. At low physiological levels (pM 
range) Aβ acts as a positive neuromodulator, as previously mentioned, and, interestingly, 
Aβ monomers were found to be neuroprotective via the PI3-kinase/Akt pathway through 
involvement of IGF-1/insulin receptors [128], resulting in downstream activation of CREB 
via phosphorylation [105]. While maintaining Aβ in monomeric form would be difficult if 
not impossible, a N-terminal fragment of Aβ (1-15/16) naturally derived from Aβ by the 
action of α-secretase, which does not oligomerize was shown to be responsible for the 
neuromodulatory activity of Aβ [62]. 
 
 
 
1.4 Neuroprotective Pathways 
1.4.1 Inflammation 
Chronic inflammation in the CNS has been shown to be associated with many 
neurodegenerative diseases, including AD [150, 151].  The two main factors believed to 
contribute to inflammation-induced neuronal death in AD are the increases in fibrillary Aβ 
deposits [152] and microglia activation [153, 154].  In the early stages of AD, low-levels 
of proinflammatory cytokines continuously act on microglia over a long period of time, and 
with the progression of the disease, elevated levels of Aβ exacerbate microglia activation, 
further increasing the expression of inflammatory genes [153]. 
Nuclear factor-κB (NF-κB) is a transcription factor involved in many biological 
processes including the regulation of cytokine production.  Activation of NF-κB by TNF-α 
(tumor necrosis factor α), interleukin 1β (IL-1β) and lipopolysaccharide (LPS) via the 
canonical pathway or by LT(lymphotoxin)α/β, a CD40 ligand acting via the non-canonical 
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pathway [155] induces the production of inflammatory and oxidative stress related genes 
[156].  Interestingly, postmortem AD patient brain tissues show an increase in NF-κB 
activity in neurons and astrocytes surrounding Aβ plaques [157], and NF-κB is activated 
by Aβ in cultured neurons [158].  Targeting the reduction of NF-κB activity by inhibiting 
activation or DNA binding reduces microglia activation and subsequently the release of 
pro-inflammatory factors [159–161] resulting in cell survival.  Unfortunately, inhibitors 
blocking NF-κB activity may consequently exacerbate the neurodegenerative processes 
by preventing the release of cytokines for neuroprotection, interfering with the critical 
physiological role of NF-κB. 
 
1.4.2 Oxidative Stress 
Oxidative stress is considered an essential factor in many neurodegenerative 
diseases and is believed to play an important mechanistic role in age-related 
degenerative processes.  Increases in oxidative stress cause damage to lipids, DNA, 
proteins, mitochondrial damage and eventually cell death.  Unfortunately, the brain is 
more sensitive than most other tissues to oxidative stress due to its low levels of protective 
enzymes such as glutathione peroxidases (GPxs), catalase [162] and superoxide 
dismutases (SODs) [163] underlying its inadequate ability to neutralize the ROS and RNS 
(reactive nitrogen species) [164].  Additionally, activated microglia contribute to oxidative 
stress in neurodegenerative disorders [165, 166].  It has also been shown that activation 
of Nrf2 in macrophages and microglia down-regulates NF-κB-induced inflammatory 
responses [167, 168].     
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The NrF2 signaling pathway plays a major role in protecting against oxidative 
stress [169, 170] by transcriptionally activating protective genes through the antioxidant 
response element (ARE) [171, 172].  AREs are promoter elements upstream of 
biotransformation phase II detoxifying enzymes and factors necessary for survival such 
as SODs [173], GPxs [174], catalase [175] and nicotinamide adenine dinucleotide 
phosphate (NADPH) [176].  Growing evidence has shown that the AD brain is under 
tremendous oxidative stress [110–112].  Notably, staining of hippocampal neurons in 
post-mortem AD patients showed a significant reduction of nuclear Nrf2 compared to 
normal cells, suggesting that Nrf2 was not being properly translocated into the nucleus 
[177], therefore Nrf2-mediated transcription was not being induced.  Considering the 
evidence, studies targeting the Nrf2-ARE pathway for protection against oxidative stress-
induced cellular death [178, 179] show promising results but the long-term 
neuroprotective effects still remain to be shown.     
 
1.4.3 Mitochondrial Dysfunction  
Mitochondria play important roles in cell survival and death by regulating energy 
metabolism and various death processes.  Given their role in energy metabolism by 
oxidative phosphorylation, mitochondria convert 1-5% of the cellcular oxygen to ROS due 
to the leakage of electrons from the electron transport chain [180], making them one of 
the main producers of intracellular ROS under physiological conditions.  Alternatively, 
under pathological conditions, the excess production and the cell’s inability to neutralize 
ROS leads to oxidative stress-induced damage as previously mentioned.  Mitochondrial 
dysfunction is one of the initial stages in apoptosis, and substantial evidence suggests 
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mitochondrial dysfunction as a key player in AD pathogenesis [181].  Taken further, some 
researchers have postulated that mitochondrial dysfunction is the primary event that 
triggers Aβ deposition, synaptic loss and dysfunction and tau neurofibrillary tangles [182].   
The expression levels of SIRT1 (sirtuin family member 1), an NAD+-dependent 
enzyme that regulates mitochondrial biogenesis [183], were shown to be significantly 
reduced in the parietal cortex of AD patients and negatively correlated with the 
accumulation of tau, suggesting that SIRT1 is associated with AD progression [184].  By 
contrast, the activation and overexpression of SIRT1 has been shown to be 
neuroprotective against neurodegenerative diseases [185, 186] by upregulating the 
peroxisome proliferator-activated receptor gamma coactivator-1α (PGC1α), a regulator 
of mitochondrial biogenesis [187].  Various compounds have already been found to be 
neuroprotective through upregulating SIRT1 [188, 189].   
The peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear 
receptor that controls many physiological and pathological processes [190], mainly lipid 
and glucose metabolism.  Dysfunctional PPARγ has been implicated in many diseases of 
the CNS [191], and PPARγ agonists have been shown to ameliorate Aβ-induced learning 
and memory deficits [192, 193] as well as downregulate caspase 3 and 9 activity and 
upregulate PGC1α [194].  Increasing mitochondrial biogenesis by upregulating PGC1α 
through SIRT1 or PPARγ is a potential target to protect against mitochondrial dysfunction 
under pathological conditions.   
      While receptor-activated pathways have been linked to mitochondrial dysfunction, 
there is evidence that internalized Aβ binds with an Aβ-binding alcohol dehydrogenase 
(ABAD) [195] located in the mitochondria.  ABAD plays an important role in metabolic 
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homeostasis and the Aβ-ABAD interaction affects this homeostasis and promotes 
mitochondrial generation of free radicals [196], thus, leading to an increase in cellular 
stress and eventually apoptosis. The extent to which Aβ receptor-linked pathways and 
internalized Aβ contribute to mitochondrial dysfunction and oxidative stress remains to be 
resolved. 
 
1.4.4 Excitotoxicity 
Glutamate, the main excitatory neurotransmitter in the CNS, binds to a variety of 
receptor-linked cation channels to modulate synaptic plasticity and learning and memory 
[197].  As noted before, excess amounts of glutamate lead to dysfunctional Ca2+ 
homeostasis [27, 198], and increase extracellular glutamate by inhibiting re-uptake [125, 
126], subsequently eliciting excitotoxicity and cellular death.  Glutamate receptor-
mediated excitotoxicity has been linked to various diseases [199–201].  Additionally, Aβ 
has been implicated in triggering excitotoxicity in AD through sustained activation of 
NMDA (N-methyl-D-aspartate)-type and AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) glutamate receptors.  This in turn, causes elevated intraneuronal 
Ca2+ levels due to excess glutamate from oxidative stress and Aβ accumulation [121, 
122].  Of the two FDA-approved drugs on the market to treat AD, the NMDAR antagonist 
memantine effectively blocks prolonged receptor activity, improving patient behavior and 
cognition [130], making it a potential agent against glutamate-mediated neurotoxicity [95, 
202, 203].  The success of memantine on improving AD behavioral symptoms coupled 
with the fact that other agents have also been shown to protect against excitotoxicity by 
inhibiting various glutamate receptor activities [92, 204–206] makes targeting glutamate 
toxicity an attractive pathway for neuroprotection.   
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1.4.5 Synaptic Dysfunction 
Synapses are involved in information transfer in the CNS and synaptic dysfunction 
is a major factor in neurodegenerative diseases [207] causing severe cognitive decline 
[208].  In AD, the over-accumulation of Aβ continuously acts on NMDARs causing Ca2+ 
deregulation and oxidative stress [122] leading to synaptic loss and toxicity.  Under these 
conditions, the activation of stress-kinases [209, 210] and caspases [211, 212] have been 
linked to synaptic and cognitive dysfunction. NMDA receptors have been extensively 
implicated in synaptic plasticity involved in learning and memory, and the abnormal 
stimulation of NDMA receptors leads to excitotoxicity (as mentioned earlier).  In addition, 
reductions in NMDA receptors in the hippocampus and cortex of postmortem AD have 
also been observed [213].  Aside from utilizing NMDA receptor antagonists for 
neuroprotection against excitotoxicity, targeting downstream pathways may provide an 
alternative method to rescue synaptic toxicity by upregulating NMDA receptor expression 
and/or activity.  Downstream targets of interest include CREB and its upstream regulator 
protein kinase A (PKA), Ca2+/calmodulin-dependent protein kinase II (CAMKII), 
calcineurin and protein phosphatase 1 (PP1) [214, 215].  BDNF, an important regulator 
in synaptic plasticity [148, 216], upregulates CREB, which in turn, enhances expression 
of BDNF in a feed-forward mechanism.   
Autophosphorylation of CAMKII is associated with an increase in Ca2+-
independent protein kinase activity linked to LTP enhancement under physiological 
conditions, whereas dephosphorylation prevents LTP [217] and leads, eventually, to 
memory impairments. Specifically, activated CAMKII has been shown to translocate to 
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the nucleus in post-synaptic neurons upon Ca2+ influx through NMDA receptors [218] 
during LTP induction [219], mediating the downstream impact of NMDA receptor 
activation resulting in long-lasting molecular changes responsible for synaptic plasticity, 
learning and memory [220–222]. In postmortem tissue of AD patients, a significant loss 
of CAMKII-expressing neurons was observed in the hippocampus [223], and altered 
expression and activity of CAMKII were found in AD mouse models [224, 225]. 
Considering its evident loss of expression and activity in disease models, inhibitors of 
CAMKII-dephosphorylation (via phosphatase inhibition) may be another target to 
maintain synaptic integrity and function. 
Calcineurin is another Ca2+/calmodulin-dependent protein that is a protein 
phosphatase implicated in various signaling transductions.  Dysfunction of calcineurin is 
also associated with pathological Ca2+ signaling in cognitive disorders and impairments 
in LTP and LTD.  In vitro, excess Aβ increases the activity of calcineurin, which, in turn, 
decreases AMPA receptor function.  This results in enhanced LTD [211] and decreased 
CAMKII activity [217] preventing LTP .  Alternatively, inhibition of calcineurin reverses Aβ-
dependent learning and memory impairments [226], reduces Aβ-induced neuronal and 
dendritic spine loss [227], and rescues early synaptic plasticity deficits [228].  Additionally, 
the pathophysiological activation of calcineurin activates the phosphatase PP1 [229], 
which negatively regulates PKA [230] and deactivates CAMKII [231], affecting synaptic 
plasticity and survival. Furthermore, calcineurin also activates the nuclear factor of 
activated T cells (NFAT) which subsequently leads to dendritic spine loss and neuritic 
dystrophies [232].  Thus, targeting PP1 activity may provide another neuroprotection 
avenue.  
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In the CNS, nitric oxide (NO) is a “gasotransmitter” (gaseous signaling molecule) 
that plays an important role in brain activity as a retrograde neurotransmitter or a mediator 
of toxicity [233]. In addition to being involved in vasodilation, NO is involved in learning 
and memory through LTP induction [234, 235] by interacting with soluble guanylyl cyclase 
(sGC) to increase cGMP (cyclic guanosine monophosphate) to elicit a cGMP-dependent 
release of glutamate [236], known as the NO-cGMP cascade.  As previously mentioned, 
physiological levels of glutamate are necessary for synaptic plasticity, learning and 
memory [197], but  under pathological conditions, the overproduction and accumulation 
of NO contributes to cell stress that leads to altered intracellular signaling, protein 
misfolding, mitochondrial damage, synaptic dysfunction and apoptosis [237, 238].  
Restoring NO signaling in the brain to improve blood flow, modulate inflammation or 
enhance synaptic viability and function is already under investigation [239–241].  
 The mitogen-activated protein kinase (MAPK) cascades are a major signaling 
pathway for neuronal survival, proliferation and differentiation [242].  Of the key regulators 
in the MAPK pathway, activation of c-Jun amino-terminal kinase/stress-activated protein 
kinase (JNK) and p38 are strongly associated with LTP impairments [243, 244].  Studies 
have shown that inhibition of JNK and p38 improves synaptic plasticity and cognitive 
deficits [245, 246], suggesting that MAPK inhibitors may protect against synaptic 
dysfunction.   
 
1.4.6 Apoptosis  
Modulating neuronal survival signaling to inhibit apoptosis or upregulate anti-
apoptotic pathways is another avenue for neuroprotection.  Proteins in the Bcl-2 family, 
consisting of both pro-apoptotic and anti-apoptotic proteins, and members of the caspase 
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family play critical roles in controlling activation and transduction of apoptosis [247, 248].  
The increase in pro-apoptotic activity results in mitochondrial dysfunction and release of 
cytochrome C [249] subsequently activating the intrinsic apoptotic pathway.  In addition, 
increases in oxidative and ER stress activate the unfolded protein response (UPR) in the 
ER [250] causing ER stress-induced apoptosis.  Compounds targeting apoptosis exert 
their neuroprotective effects by reducing pro-apoptotic Bcl-2 and caspase members [251–
253] or by reducing ER-induced apoptosis [254, 255]. 
In addition to preventing apoptosis, modulating neuronal survival signals is another 
target for neuroprotection. Within the MAPK pathway, activity of the extracellular signal 
regulated protein (ERK), JNK and p38 are upregulated with elevated levels of Aβ in vivo 
[256] and in vitro [136], suggesting that the MAPK pathway is also associated with AD 
pathology.  Inhibitors of ERK, JNK and p38 have been extensively studied as potential 
therapeutic agents against neurodegenerative diseases [257, 258], improving spatial 
learning and memory impairments and neuronal survival [259, 260].  
 
1.4.7 Cell Survival 
Neurotrophins play an important role in the development, maintenance, repair and 
survival of neurons.  Studies have shown that neurotrophins inhibit cell death [261, 262] 
and promote neuronal survival [101] through the activation of multiple transcription 
factors, such as CREB, to induce the expression of prosurvival and prodifferentiation 
genes [263].  As previously noted, CREB is believed to upregulate neurotrophin 
expression and activity.  Addittionally, CREB is also activated in response to stressful 
stimuli [264] through the MAPK [265], PI3K/AKT [266], NF-κB [267], and PLCγ/PKC and 
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cAMP/PKA [268] pathways leading to the expression of the pro-survival gene bcl-2 [147].  
In light of the fact that decreased expression of BDNF plays an important role in various 
neurodegenerative disorders [269] and CREB has been shown to be downregulated in 
hippocampal neurons in AD models [105], a means to increase CREB activity may 
provide a potential neuroprotective avenue.    
Another important survival pathway involved in synaptic plasticity, axonogenesis, 
neural development and neural homeostasis is the Wnt signaling pathway [270].  The 
activation of the Wnt pathway attenuates cytosolic glycogen synthases kinase 3β (GSK-
3β ), thereby increasing β-catenin nuclear translocation and subsequently upregulating 
proteins involved in neural development and homeostasis [270].  Activation of the Wnt 
pathway may provide an alternative target for neuroprotection [271, 272] with several 
groups already investigating molecules capable of upregulating this pathway [273, 274].  
Taken together, the evidence shows that modulating the apoptotic or survival pathways 
may provide good targets for neuroprotection.  
 
1.5 Concluding Remarks 
Although a considerable amount of research and time has been spent exploring 
and developing protective therapies against Aβ toxicity, to date, none of these 
neuroprotective agents has yet been shown to provide neuroprotection in AD, as defined, 
namely altering or rescuing the course of the disease. The development of an effective 
neuroprotective compound against AD may be limited by a number of factors in addition 
to those already outlined.  First, it is imperative to begin treatment with an agent able to 
penetrate the BBB, whether orally, systemically or intranasally administered, at the right 
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window of opportunity to ensure neuronal and synaptic protection against toxicity leading 
to any further damage. In some cases, the agent may also need to be able to penetrate 
intracellularly to act on intracellular targets. Second, low levels of Aβ have an important 
physiological function [36] and disruption of this homeostasis may contribute to toxicity. 
Third, neuroprotective therapeutics should not only preserve existing and surviving 
neurons but should also improve their function, including plasticity and adaptability.  
Lastly, neuroprotection against Aβ toxicity cannot be limited to a single target or pathway 
due to the fact that AD is a multifactorial disorder that involves multiple biological 
pathways (Fig. 3).  Although the development of a potent and effective therapeutic against 
Aβ toxicity has yet to prove successful in clinical trials, progress is underway in identifying 
agents that will hopefully meet the standards of definition for neuroprotection in AD 
models in the near future. 
There are currently only two classes of FDA-approved drugs for AD treatment, 
cholinesterase inhibitors and the NMDA-type glutamate receptor antagonist.  Although 
these drugs are somewhat efficacious in treating the symptoms of AD for some patients 
over a limited period of time, unfortunately, none is capable of reversing the course of AD 
or even significantly slowing down the rate of progression. Therapeutic implementation of 
neuroprotective approaches offers, on the other hand, a direct means to prevent or 
reduce, if not reverse, disease progression. In a survey of the most recent agents with 
demonstrated protective activity toward Aβ toxicity, only a minor subset displays 
neuroprotection at the synaptic, cellular and behavioral levels [98, 275, 276]. 
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1.6 Hypothesis 
The N-Aβcore, accounting for the neuromodulatory activity of Aβ, protects against 
Aβ-induced mitochondrial dysfunction, oxidative stress and apoptotic neuronal death, and 
rescues Aβ-induced synaptic dysfunction. 
 
Figure 3: Prominent Aβ-induced Ca2+ Dysregulation Toxicity Pathway 
Aβ-induced elevation of neuronal Ca2+ elicits various signaling cascades that subsequently induce 
apoptosis, mitochondrial dysfunction, oxidative stress, ER stress and synaptic dysfunction.  
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1.7 Specific Aims 
1.7.1 Specific Aim 1 
Aim 1A:  To assess the N-Aβcore and its mutants for neuroprotection against Aβ-induced 
neurotoxicity.  
 
Aim 1B:  To characterize differential changes of presynaptic Ca2+ responses of the N-
Aβcore and mutants. 
 
Rationale: Preliminary data suggest that the main active part of Aβ and the N-Aβ fragment 
is the N-Aβcore [62], and Aβ monomers were found to be neuroprotective via the PI3-
kinase/Akt pathway [128].   We propose that the core sequence is neuroprotective against 
Aβ-induced apoptosis. 
 
1.7.2 Specific Aim 2 
Aim 2A:  To examine the neuroprotective effects of the N-Aβcore on Aβ-induced synaptic 
dysfunction 
 
Aim 2B:  To elucidate the neuroprotective pathway of the N-Aβcore. 
 
Rationale: Previous work has shown that endogenous pM levels of Aβ and the N-Aβ 
fragment enhance synaptic plasticity [36, 62].  Additionally, the N-Aβ fragment prevents 
Aβ-induced inhibition of synaptic plasticity [62].  Therefore, we propose that the N-Aβcore 
can rescue Aβ-induced synaptic dysfunction.  Furthermore, as an extensive amount of 
research has been focused on understanding Aβ toxicity and Aβ-independent 
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neuroprotective pathways, we aim therefore to elucidate the protective mechanism(s) of 
the N-Aβcore. 
 
 
1.8 Significance  
Characterization of the relative activity of N-Aβcore and mutants to protect against 
Aβ toxicity allowed optimization of a core sequence that will serve as a scaffold for 
synthesis of orally active peptidomimetics.  Additionally, the understanding of the 
neuroprotective action of the N-Aβcore will provide additional insights to potential targets 
for AD therapeutics.   
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CHAPTER 2: THE NEUROPROTECTIVE EFFECTS OF THE N-AβCORE 
ON Aβ-INDUCED NEUROTOXICITY AND THE DIFFERENTIAL CALCIUM 
CHANGES OF THE N-AβCORE  
 
2.1 Introduction 
Alzheimer disease (AD) is a progressive neurodegenerative disease characterized 
by synaptic and neuronal loss in regions of the brain critical for memory and cognition. 
Histologically, AD is characterized by tau containing neurofibrillary tangles and beta 
amyloid (Aβ) plaques [277], the latter resulting from the over-accumulation of soluble Aβ 
years prior to a diagnosis of AD (reviewed in [278]). In contrast, the levels of Aβ normally 
present in brain in the absence of AD, estimated to be in the picomolar (pM) range, have 
been found to enhance synaptic regulation [32, 33], synaptic plasticity [34–36] and fear 
memory [32]. In addition, Aβ is produced and released from the presynaptic terminal [279] 
in an activity-dependent manner [34] and has a remarkably high turnover rate [280]. 
Together, these findings suggest that Aβ functions physiologically as a neuromodulator. 
As Aβ accumulates to nanomolar (nM) levels or higher during the prodromal stages of 
AD, dysfunction of synaptic signaling and memory processing ensues [20, 124]. 
Aβ is produced through the sequential enzymatic cleavage of the amyloid 
precursor protein (APP) via β- and γ-secretases [58]. As Aβ is partially derived from the 
transmembrane (TM) domain of APP, the peptide has a C-terminal hydrophobic domain, 
which has been shown to largely but not exclusively account for its aggregation and 
neurotoxicity [59, 60]. In contrast, a larger hydrophilic domain resides on the N-terminal 
side of the peptide. It has been shown that a 15-16 amino acid N-terminal Aβ fragment 
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(N-Aβ fragment) can be produced from this hydrophilic domain via an α-secretase-linked 
pathway and is present at significant levels in cerebrospinal fluid (CSF) [15].  
Previous work indicated that the Aβ N-terminal domain is non-toxic [281]. Through 
structure-function analysis, we have shown that Aβ’s neuromodulatory agonist-like 
activity toward nicotinic acetylcholine receptors (nAChRs) is contained within the 
hydrophilic N-terminal domain [62]. Moreover, we discovered that at pM-nM 
concentrations, the N-Aβ fragment is approximately twice as effective as Aβ in stimulating 
receptor-linked increases in Ca2+, enhancing long-term potentiation (LTP) and enhancing 
contextual fear conditioning (CFC) [62]. Additionally, treatment of hippocampal slices from 
transgenic mice expressing the Swedish mutation APP (hAPPswe: B6.SJL-
Tg(APPswe:APP695K670N,M671L)2576Kha) with the N-Aβ fragment rescued LTP 
deficits shown to exist in this APP-AD mouse model [62] as the result of elevated Aβ.  We 
further narrowed down the core sequence accounting for the activity of the N-Aβ 
fragment, identifying an essential and unique core hexapeptide sequence, YEVHHQ (N-
Aβcore). It was found to be as effective as the N-Aβ fragment in eliciting Ca2+ responses 
through nAChRs [62]. 
To investigate the possible impact of the N-Aβcore on full-length Aβ-induced 
neuronal toxicity in a model neuronal system (neuroblastoma cell line NG108-15), we 
studied Aβ-triggered Ca2+ responses, oxidative stress, and apoptosis offers a novel 
avenue for the development of AD therapeutics.  
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2.2 Methods 
2.2.1 Neuroblastoma Clonal Cell Culture and Transfection  
Rodent hybrid neuroblastoma NG108-15 cells (courtesy of Dr. William Atchison, 
Michigan State University) were used as a model nerve cell system allowing reconstitution 
with defined target receptors for Aβ [146].  The cells were cultured in high-glucose 
Dulbecco’s modified Eagle’s medium (DMEM) containing 15% fetal bovine serum (FBS) 
and differentiated in the presence of reduced serum (1% FBS) and 1mM dibutyryl cyclic 
AMP for 72h. Under these differentiation conditions, the cells extend axonal processes 
having presynaptic varicosities (identified morphologically and by presynaptic markers) 
capable of forming cholinergic synapses with the appropriate postsynaptic target [282].  
Expression vectors (pcDNA3.1) containing mouse sequences for α4 and β2 nAChR 
subunits (courtesy of Dr. Jerry Stitzel, University of Colorado) were transiently transfected 
into the cells at 1:4 ratio, respectively, using FuGENE HD (ThermoFisher, catalog # 
PRE2311) for 48h. Mock-transfected NG108-15 cells, exposed only to FuGENE HD and 
not plasmid DNA, were used as controls [33]. 
 
2.2.2 Confocal Imaging of Intracellular Calcium  
Changes in intracellular Ca2+ levels in individual varicosities of differentiated 
NG108-15 cells were monitored by the Ca2+-selective fluorescent dye Fluo-4, as 
described [146].  Fluo-4/AM (Invitrogen, catalog # F23917) was loaded into the 
differentiated cells cultured on Cell-Tak-coated coverslips. Fluo-4-loaded cultures were 
perfused with oxygenated HEPES-buffered saline (HBS: 142 mM NaCl, 2.4 mM KCl, 1.2 
mM K2PO4, 1 mM MgCl2, 1 mM CaCl2, 5 mM D-glucose, 10 mM HEPES (pH 7.4), 100 
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nM tetrodotoxin, TTX) via a rapid exchange Warner perfusion chamber. Changes in 
fluorescent intensity (F) in response to various treatments (Aβ alone or in combination 
with N-Aβ fragment or N-Aβcore with pretreatment, co-treatment or post-treatment; Aβ or 
the N-Aβ fragment followed by co-treatment with the N-Aβcore) were visualized by a 
Nikon PCM 2000 Chameleon confocal imaging system.  Each time-series was normalized 
to baseline fluorescence intensity at time zero (F0) to yield the relative change in Ca2+i 
(as F/F0).  Peak responses for four to ten varicosities per sample were collected during 
60–180s after the initiation of stimulation and determined across all frames using ImageJ 
software.   
 
2.2.3 Mitochondrial Membrane Potential 
The mitochondrial membrane potential was measured using TMRE (tetramethyl 
rhodamine ethyl ester)- mitochondrial membrane potential assay kit (Invitrogen, catalog 
# T669).  Briefly, nAChR-transfected NG108-15 cells were treated over one to five days 
with either Aβ or Aβcore. The cells were incubated with 50nM TMRE in HBS for 20 
minutes and imaged live using an Olympus IX71 epifluorescence microscope at 
excitation/emission of 549/575nm, respectively.  
 
2.2.4 Reactive Oxygen Species (ROS)/ Hoechst staining  
Oxidative stress was determined by changes in the levels of ROS using the Image 
iT Live Reactive Oxygen Species (ROS) Detection kit (Invitrogen, catalog # I36007) [283]. 
In brief, NG108-15 cultures were subjected to various treatments for three days.  The 
medium for each treatment condition was changed every day, unless otherwise noted. At 
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the end of the treatment periods, the cells were incubated with carboxy-H2DCFDA 
(component A) at 37°C for 30 min. During the last 5 min of incubation, 2 µg/ml of 
HOECHST stain (component B) was added to assess, in parallel, the integrity of the cell 
nuclei. The cells were washed twice with HBS and visualized using an Olympus IX71 or 
IX81 epifluorescence microscope at excitation/emission of 495/529 nm (ROS) and 
350/461 nm (HOECHST), respectively. 
 
2.2.5 Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick-End Labeling 
(TUNEL) Assay 
Apoptosis was measured using TUNEL staining via a Click-iT TUNEL Alexa 
Fluor488 Imaging Kit (Invitrogen, catalog # C10245) in accordance with the 
manufacturer’s protocol [136]. In brief, the cells were subjected to various treatments for 
four days, exchanging the medium each day. After the fourth day of treatment, the cells 
were fixed with freshly prepared 4% paraformaldehyde (neutralized with NaOH while 
heating to produce formaldehyde) in PBS for 20 min and permeabilized with Triton X-100 
(0.25% in PBS) for another 20 min. The cultures were then washed twice and incubated 
with 50µL of terminal deoxynucleotidyl transferase reaction buffer (Component A) for 10 
min. The buffer was replaced with TUNEL reaction mixture containing terminal 
deoxynucleotidyl transferase and incubated in a humidified chamber at 37°C for 60 min. 
The cells were then washed three times with 3% bovine serum albumin (BSA) in PBS for 
2min each and thereafter, incubated with 50µL of Click-iT reaction mixture (containing 
Alexa 488 azide) for 30 min at room temperature, protected from light exposure. The cells 
were again washed with 3% BSA in PBS and the cell nuclei were counterstained with 
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Hoechst 33342 for 15 min at room temperature, protected from light. The coverslips were 
washed twice with PBS before mounting onto a slide with Vectashield mounting medium 
(Vector Laboratories, Burlingame,CA). 
 
2.2.6 Human Aβ and Derivatives   
Full-length Aβ and the N-Aβ fragment were obtained as hydrochloride salts from 
American Peptide/ BACHEM (Aβ: catalog # 62-0-80; N-Aβ fragment: 62-1-04) or Anaspec 
(Aβ: catalog # AS-21793; N-Aβ fragment: AS-61798). The N-Aβcore and mutants were 
custom-ordered from Peptide 2.0. (Comparison of the peptides from various sources 
yields equivalent neuromodulatory activities. There is no evidence that the N-Aβcore has 
an effect on Aβ oligomer formation.) All peptides were synthesized and isolated at >98% 
purity, as assessed by mass spectrometry and high-performance liquid chromatography.  
Aβ (1-42), the N-Aβ fragment (1-15), and the N-Aβcore (10-15) and mutant forms were 
solublized in double-distilled water and used at pM to nM final concentration in buffered 
saline [33].  
 
2.2.7 Reagents 
All standard reagents (buffers, salts, tissue culture media and substrates, 
paraformaldehyde, Triton X-100, etc.) were obtained from Sigma or ThermoFisher and 
were of the highest grade available (>98% purity). Plasmid purification maxiprep kits were 
from Qiagen (catalog # 12262) or Zymo Research (catalog# D4202). FBS was purchased 
from Omega Scientific (catalog # FB-11, Lot # 514205).  Tetrodotoxin was purchased 
from Abcam (catalog # ab120054, Lot # GR169765).  BD Cell-Tak was obtained from 
VWR (catalog # 47743-684, Lot # 7100009).  
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2.2.8 Statistical Analyses   
Treatment and units were randomized as to order for all assays and experiments. 
Biological replicates were based on independent samples (n). All experiments were 
repeated at least three times.  All quantitative results are presented as boxplots (5-95% 
confidence intervals), where appropriate, or means ± SEM. Statistical analyses were 
performed using Prism (GraphPad v5.0b; RRID:SCR_002798). Multiple comparisons 
were made using one-way ANOVA with Bonferroni or Tukey post hoc tests, as indicated. 
Paired comparison was made using Student’s t-tests. P-values <0.05 were considered 
the minimum for significance (as rejection of the null hypothesis).  
 
2.3 Results 
2.3.1 N-Aβcore and N-Aβ fragment are highly effective, potent activators of α7- and 
α4β2-nAChRs 
We have previously shown that the N-Aβcore (10-15) and N-Aβ fragment (1-15) 
have similar potencies to that of Aβ1-42 as neuromodulators, measured as changes in 
presynaptic Ca2+ in the axonal varicosities of α7-nAChR-transfected, differentiated 
neuroblastoma NG108-15 cells used as a reconstituted model neuronal system [62].  In 
order to determine the key functional residues in the core sequence, YEVHHQ, screening 
of numerous N-Aβcore mutants was performed using Fluo-4 to measure relative changes 
in intracellular Ca2+. We found that mutating the His-13 and His-14 to Ala-13 and Ala-14 
(H13A,H14A), respectively, reduced activity compared to the wild-type N-Aβcore 
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(p<0.001), whereas mutating the Gln-15 to His-15 (Q15H) showed a trend towards an 
increase in activity (Fig. 4A).   
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Figure 4: Mutational-analysis of the N-Aβcore using NG108-15 cells expressing α7- or 
α4β2-nAChRs. 
Top, the human N-Aβ fragment sequence, highlighting the N-Aβcore (shaded) A, Relative 
average peak Ca2+ responses in the axonal varicosities of differentiated NG108-15 cells 
expressing α7-nAChRs to 100nM Aβ1-42 (n=44), N-Aβcore (n=70), N-Aβ fragment (n=178), [Y10A] 
N-Aβcore (n=14), [H13A,H14A] N-Aβcore (n=19), and [Q15H] N-Aβcore (n=33).  B, Relative 
average peak Ca2+ responses in varicosities of differentiated NG108-15 cells expressing α4β2-
nAChRs to 100nM Aβ1-42 (n=36), N-Aβcore (n=32), N-Aβ fragment (n=35), [Y10A] N-Aβcore 
(n=21), [H13A,H14A] N-Aβcore (n=19), and [Q15H] N-Aβcore (n=29). n refers to the number of 
individual varicosities. Averaged data are means ± SEM, normalized to the average peak Ca2+ 
responses N-Aβcore (dashed lines). *p<0.05 and ***p<0.0001 (Bonferroni post hoc tests for 
comparison with the N-Aβcore).   
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 An alanine scan across the remaining residues of the N-terminal of the N-Aβcore 
resulted in no significant change in the α7-nAChR-linked Ca2+ responses (Table 1). These 
findings suggest that His-13 and His-14 are critical in eliciting activity, which is consistent 
with previous mutational analysis of N-Aβ fragments [284, 285] as well as full-length Aβ 
[62, 286].   
 
To translate these findings into our neuronal toxicity model, we performed a similar 
set of experiments with α4β2-nAChR-transfected cells, which were previously shown to 
respond to Aβ1-42 in an α4-dependent manner [136].  Using the same approach, we 
demonstrated that the N-Aβcore and the N-Aβ fragment retain their neuromodulatory 
 
 
Average peak Ca2+ responses in axonal varicosities of differentiated NG108-15 cells 
expressing α7-nAChRs or α4β2-nAChRs to various N-Aβcore alanine and truncation mutants, 
expressed as % ± S.D. of the average peak Ca2+ response to the N-Aβcore. N is the number 
of varicosities. 
Table 1. Averaged Ca2+ changes in NG108-15 cells on stimulation with N-Aβcore alanine 
and truncation mutants. 
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activity at nM (Fig. 4B; Fig. 5) and pM (Fig. 5) concentrations.  In accordance with our 
earlier findings, the H13A,H14A mutation reduced activity compared to the N-Aβcore 
(p<0.05), whereas the Q15H mutation showed a trend towards an increase in activity (Fig. 
4B).  In contrast, mutation of Glu-11 and Val-12 to Alanine showed no difference in activity 
(Table 1). However, a significant reduction was observed on mutating Tyr-10 to an 
Alanine when compared to the wild-type N-Aβcore (Fig. 4B; p<0.05 vs. wild-type).  
Mutation of Tyr-10 to a Serine also significantly reduced activity in both α7- and α4β2-
nAChR-transfected cells (Table 1), with a trend evident in the truncation mutants with 
removal of this tyrosine. This loss in activity suggests that the tyrosine residue also plays 
a role in the N-Aβcore’s activity toward α4β2-nAChRs, possibly through the aromatic and 
hydroxyl moieties [33].  We have previously shown that Tyr-188 in the ligand binding 
domain of α7 nAChR plays an essential role in the agonist action of Aβ in presynaptic 
regulation [33] and thus ligand-target aromatic side chain interactions may be involved. 
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2.3.2 Prolonged treatment with the N-Aβcore elicits a transient Ca2+ response, 
whereas the N-Aβ fragment induces a sustained but attenuated response 
compared to full-length Aβ 
To mimic prolonged exposure of neurons to amyloid peptides, we measured the 
effects of Aβ1-42, N-Aβcore or N-Aβ fragment on α4β2-nAChR-linked Ca2+ responses in 
our neuronal model over an extended period of time. Treatment with 100nM Aβ1-42 
induced a long, sustained increase in Ca2+ out to tens of minutes (Fig. 6A), similar to 
previous findings [146]. The N-Aβ fragment (100nM) also elicited a sustained but 
significantly reduced response. In contrast, 100nM N-Aβcore induced only a transient 
spike in activity that peaked at 2 min of treatment, returning back to baseline after 4 min 
(Fig. 6A).  These findings suggest that the N-Aβcore and N-Aβ fragment differentially 
couple to target receptors to induce changes in internal Ca2+ in comparison to the 
sustained changes on prolonged exposure to Aβ1-42, which likely lead to dysregulation of 
mitochondria [136, 287]. The extent to which these differences in primary signaling 
account for the absence of toxicity for these N-Aβ fragments remains to be determined. 
However, co-treatment with N-Aβcore following prolonged application of Aβ1-42 or the N-
Aβ fragment strongly attenuated the Ca2+ responses (Fig. 6B). 
Figure 5: Lower concentrations of N-Aβcore and N-Aβ fragment retained significant Ca2+ 
activity. 
Average peak Ca2+ responses in axonal varicosities of NG108-15 cells expressing α7-nAChRs to 
100pM N-Aβcore (n=8), 100nM N-Aβcore (n=70), 100pM N-Aβ fragment (n=32) or 100nM N-Aβ 
fragment (n=178).  Averaged data are means ± SEM and dashed lines indicate the average 
maximal responses of N-Aβcore. n is the number of varicosities. 
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2.3.3 The N-Aβcore rescues mitochondrial dysregulation induced by prolonged 
Aβ1-42 exposure 
Mitochondrial damage and dysfunction in AD due to the dysregulation of Ca2+ 
signaling has been widely reported [288, 289]. We have previously shown that prolonged 
exposure to Aβ1-42  in our toxicity model altered mitochondrial dynamics, transport and 
Figure 6: The N-Aβcore elicited a short-lived Ca2+ response compared to Aβ.   
Average normalized Ca2+ responses (F/F0) in the axonal varicosities of differentiated NG108-15 
cells expressing α4β2-nAChRs to (A) 100nM N-Aβcore (n=33), 100nM N-Aβ fragment (n=17) or 
100nM Aβ1-42 (n=40) over 13 mins or (B) 100nM Aβ1-42 (n=12) or 100nM N-Aβ fragment (n=10) for 
20 mins (control) or for 15 mins followed by co-administration of 100nM N-Aβcore for 5 additional 
mins (n=32). Averaged data are means ± SEM, F0 = fluorescence at time 0, and n represents the 
total number of varicosities examined across experiments. ***p<0.001 (Bonferroni post hoc tests 
of averaged plateau values). 
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size [136].  Here, we examined the integrity of the mitochondrial membrane potential over 
five days of Aβ1-42 treatment using the cell-permeant mitochondrial membrane potential 
probe TMRE. Depolarization of the membrane potential, indicated by a decrease in TMRE 
fluorescence across the cell population, was evident after just one day of Aβ1-42 treatment 
(Fig. 7A), consistent with previous findings indicating that mitochondrial dysfunction is one 
of the earliest events in Aβ neurotoxicity [136]. Treatment for two days and longer showed 
a greater extent of inactivation of the membrane potential, indistinguishable from 2 days 
on (Fig. 7A). Co-treatment with the N-Aβcore (3-day timeframe) prevented the Aβ1-42-
triggered depolarization of the mitochondrial membrane potential (Fig.7B). 
 
2.3.4 The N-Aβcore and the N-Aβ fragment protect against full-length Aβ-induced 
oxidative stress  
We have previously shown that prolonged treatment with Aβ1-42 induces oxidative 
stress (ROS), nuclear disintegration and apoptotic cell death in our in vitro neuronal 
toxicity model [136].  To assess the potential neuroprotective effects of the non-toxic N-
Aβcore and N-Aβcore mutants against Aβ1-42-induced toxicity, we assessed these 
indicators following administration of the N-terminal peptides under various conditions 
with daily treatment with 100nM Aβ1-42 (Fig. 9). As previously shown, the presence of 
α4β2-nAChRs sensitizes the neuroblastoma NG108-15 cells to the toxicity of Aβ1-42 at 
nM concentration.  In contrast, co-treatment of α7-nAChR-transfected cells with the N-Aβ 
fragment and Aβ1-42 did not significantly protect against elevated ROS levels (Fig. 8).  Co-
treatment with the N-Aβcore at similar or higher concentrations was able to prevent Aβ1-
42-induced oxidative stress (Fig. 9B).  The rescue treatment, in which the N-Aβcore was 
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introduced into the culture for 3-, 2-, or 1-day reduced Aβ1-42-induced ROS back to 
baseline levels (Fig. 9B), suggesting that the N-Aβcore also protects against of Aβ1-42-
induced toxicity, including late stages of oxidative stress. 
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In mock-transfected cells (absent nAChRs), higher concentrations (µM) of Aβ1-42 
are required to induce significant levels of ROS. Co-treatment with nM-µM concentrations 
Figure 7: The N-Aβcore protected against Aβ-induced mitochondrial membrane 
dysregulation.    
A, Differentiated NG108-15 cells stained with TMRE (50nM) or Hoeschst (nuclei) following 3 days 
of no treatment (Untreated control), 100nM Aβ1-42 treatment or 100nM Aβ1-42 treatment plus 100nM 
N-Aβcore. B, Integrated values (ΔF/F0) for TMRE associated with individual cells (randomly 
numbered) treated for 1-5 days with 100nM Aβ1-42 (top graph) or 3 days with 100nM Aβ1-42 plus 
100nM N-Aβcore (bottom graph) are plotted as ranked distributions. 
Figure 8: Treatment of α7-nAChR-transfected cells with Aβ1-42 did not induce elevated 
levels of ROS.   
Daily treatment with either 100nM Aβ1-42 or the N-Aβ fragment alone or together in α7-nAChR-
transfected NG108-15 cells (n=3). Mock-transfected cells are represented by open bars; 
nAChR-transfected cells are represented by closed (gray) bars.  Quantification is percent of 
mean cell counts per experimental n (total number of cells).  Averaged data are means ± SEM. 
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N-Aβcore or N-Aβ fragment reduced this oxidative stress compared to Aβ1-42 alone (Fig. 
9C), demonstrating that the N-Aβcore or N-Aβ fragment can protect against Aβ1-42–
induced toxicity independently of α4β2-nAChRs. Other studies have demonstrated that 
Aβ, at higher concentrations, was able to exert its effects independently of identified 
receptors in neuronal cells [287].  
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We further examined whether the inactive [H13A,H14A] and highly active [Q15H] 
N-Aβcore mutants had any protective effect on elevated oxidative stress from Aβ1-42.  We 
found that co-treatment with nM concentrations of the active mutant reduced ROS 
compared to Aβ1-42 alone (p<0.001), whereas the inactive mutant had no significant effect 
(Fig. 9D) at the concentration tested.  These results substantiate the specificity of action 
of the N-Aβcore in neuroprotection against Aβ1-42-induced oxidative stress. 
 
2.3.5 Prolonged exposure to N-Aβcore or N-Aβ fragment protects against Aβ1-42-
induced apoptosis 
In addition to inducing oxidative stress, we have previously shown that the 
presence of α4β2-nAChRs sensitizes differentiated neuroblastoma NG108-15 cells to 
Aβ1-42-induced apoptosis [136], while elevated Aβ1-42 triggers apoptosis in the absence of 
nAChRs. Therefore, we assessed whether the N-Aβcore or the N-Aβ fragment can 
protect against Aβ1-42-induced apoptosis with or without the presence of α4β2-nAChRs.  
Co-treatment with nM concentrations of the N-Aβcore in the presence α4β2-nAChRs on 
Figure 9: The N-Aβcore and the N-Aβ fragment protected against Aβ-induced oxidative 
stress in differentiated NG108-15 cultures. 
A, Representative images of Hoechst and ROS staining.  B, Treatment with 100nM N-Aβcore 
after 0-, 1-, 2-day treatment of 100nM Aβ1-42 in the presence α4β2-nAChR (n=5). C, Treatment of 
100nm or 1µM N-Aβcore or N-Aβ fragment alone and in combination with 1µM Aβ1-42 (n=5). Note 
that in the absence of nAChRs, µM concentrations of Aβ1-42  are required to increase ROS.   Co-
treatments with Aβ1-42 are represented by closed (grey) bars. D, Co-treatment of 100nM Aβ1-42  
with 100nM [H13A,H13A] N-Aβcore or 100nM [Q15H] N-Aβcore (n=4).  For all experiments, 
mock-transfected cells are represented by open bars; α4β2-nAChR-transfected cells are 
represented by closed (gray) bars.  Quantification is ROS-positive cells as a percentage of mean 
cell counts per experimental n (total number of cells). Data are represented via box-and-whisker 
plots across 5-95 percentile range, with the lines indicating the median values. *p<0.05, 
**p<0.001, ***p<0.0001 (Tukey post hoc tests compared to positive Aβ1-42  control). ns, not 
significant. 
 
  
 
 44 
day 1, 2 or 3 following the start of daily Aβ1-42 treatment reduced apoptosis compared to 
Aβ1-42 alone (p<0.0001), as measured by TUNEL staining for apoptotic cells (Fig. 10A), 
suggesting that the N-Aβcore can protect against late stages of Aβ1-42-induced neuronal 
death.  In addition, high concentrations of Aβ1-42 induced apoptosis in the absence of the 
sensitizing α4β2-nAChRs, and co-treatments with nM-µM concentrations N-Aβcore or N-
Aβ fragment over four days also reduced DNA-fragmentation compared to Aβ1-42 alone 
(p<0.0001 for 100nM and 1µM N-Aβcore; p<0.001 and p<0.0001, 100nM and 1µM N-Aβ 
fragment, respectively), with a trend of greater reduction at µM concentrations (Fig. 10B).  
These results indicate that the N-Aβcore or N-Aβ fragment can also protect against Aβ1-
Figure 10: The N-Aβcore protected against Aβ1-42 -induced apoptosis. 
A, Co-treatment with 100nM N-Aβcore after 0-, 1-, 2-, 3-day treatment of 100nM Aβ1-42  in the 
presence of α4β2-nAChRs (n=3).  Mock-transfected cells are represented by open bars; α4β2-
nAChR-transfected cells are represented by closed (gray) bars.  B, Daily treatment of 100nM or 1µM 
N-Aβcore or N-Aβ fragment alone and in combination with 1µM Aβ1-42   (n=3). Note that in the absence 
of nAChRs, µM concentrations of Aβ1-42  are required to induce cell death. Co-treatments with Aβ are 
represented by closed (gray) bars.  Quantification is the percent of mean DNA fragmentation per 
experimental n determined from TUNEL staining. n is the number of cells. Averaged data are means 
± SEM, **p<0.001, ***p<0.0001 (Tukey post hoc tests compared to positive Aβ1-42 control). 
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42-induced neuronal death independently of the α4β2-nAChRs. 
 
2.3.6 Stabilization of N-Aβcore retains its receptor-linked Ca2+ activity and protects 
against Aβ1-42-induced neurotoxicity in α4β2-nAChR-transfected cells 
To protect the N-Aβcore from exopeptidase degradation in vivo, we capped its N-
terminus with an acetyl group and its C-terminus with an amide group.  Relative to the N-
Aβcore, the capped-N-Aβcore retained its potent activity (Fig. 11A), with a trend towards 
an increased Ca2+ response. To further protect the N-Aβcore from endopeptidase activity, 
the enantiomeric conversion from the L-configuration to the D-configuration for each 
amino acid retained activity (Fig. 11B).  In addition, the stabilized N-Aβcore, at nM 
concentrations, was as neuroprotective against Aβ1-42-induced oxidative stress as the N-
Aβcore (Fig. 11C; p<0.05 vs. Aβ1-42 alone), indicating the potential for use of the stabilized 
peptide in vivo. 
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2.4 Discussion 
A broad range of studies have shown that synaptic and behavioral dysregulation 
resulting from Aβ is mainly due to soluble oligomeric forms of the peptide, while neuronal 
toxicity leading to neurodegeneration may be triggered by these same Aβ oligomers but 
over an extended period of exposure [60].  Structural analysis indicates that the 
hydrophobic C-terminal region of Aβ, derived from the transmembrane region of APP, 
accounts for the toxicity of Aβ due to the C-terminus looping back via a turn at residues 
21-23 to form an anti-parallel beta-sheet [290], with subsequent self-association of Aβ via 
the anti-parallel beta sheets to form the aforementioned soluble, low- and high-molecular 
weight oligomers [22], not primarily the C-terminal sequence itself. While relatively high 
levels of Aβ have been shown to induce selective toxicity, we hypothesized that the N-
terminal domain has an independent function, based on our findings that Aβ has a positive 
neuromodulatory role accounted for by the N-terminal domain [62]. To address this 
possibility, we examined the impact of peptide fragments derived from the N-terminal 
domain alone and in the context of Aβ neurotoxicity. Our previous work showed that a 
Figure 11: Stabilization of the N-Aβcore retained activity and protected against Aβ1-42 -
induced oxidative stress. 
A, Average peak Ca2+ responses in varicosities of cells expressing α4β2-nAChRs to 100nM N-
Aβcore (n=51) and Capped-Aβcore (n=23).  Protection of N-Aβcore via N-terminal acetylation 
and C-terminal amidation (“Capped”) retains activity compared to N-Aβcore.  B, Peak responses 
to 100nM D-[Aβcore] (n=57) and Capped-D-[Aβcore] (n=65). Enantiomer conversion and 
stabilization of N-Aβcore retains activity.  Averaged data are mean ± S.E.M, and dashed lines 
indicate the average maximal responses of N-Aβcore.  C, Daily co-treatment with 100nM Aβ1-42 
and 100nM capped-Aβcore, D-[Aβcore] or Capped-D-[Aβcore] reduces ROS.  Mock-transfected 
cells are represented by open bars; α4β2-nAChR-transfected cells are represented by closed 
(gray) bars.  Quantification is percent of mean cell counts per experimental n. n is the number of 
varicosities.  Percent positive ROS cells represented by 5-95 percentile box-and-whiskers plots, 
*p<0.05 (Bonferroni post hoc tests compared to positive Aβ1-42 control). 
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non-toxic N-terminal fragment, found to arise endogenously from α-secretase activity in 
the brain, was more effective than Aβ in neuromodulation [62]. In our current work, it was 
found that the N-terminal peptides (N-Aβcore 10-15 and N-Aβ fragment 1-15) induced 
differential responses to calcium signaling, particularly in comparison to full-length Aβ 
which induces prolonged increases in intracellular calcium.  Aβ-induced calcium 
dyshomeostasis likely leads to mitochondrial dysregulation as well as changes in 
intracellular signaling pathways and gene expression. We further hypothesized that these 
non-toxic N-terminal Aβ peptides would be neuroprotective against Aβ1-42 neurotoxicity, 
based on our previous findings demonstrating that the N-Aβ fragment can reverse 
synaptic dysregulation resulting from full-length Aβ [62].  
Previous evidence suggested that the neuromodulatory activity of N-Aβ fragment, 
and hence Aβ, resides in a core hexapeptide sequence, YEVHHQ, encompassing 
residues 10-15 in Aβ.  Through an alanine scan, we have found the two histidine residues 
at positions 13 and 14 to be of key importance in activating the α7- and α4β2- nAChRs, 
most likely due to their specificity to the target receptors. The tyrosine at position 10 was 
also found to make a significant contribution to activation.  As previously noted, examining 
the N-Aβ fragment and N-Aβcore over a prolonged time-frame also revealed qualitatively 
different Ca2+ responses in the model neuronal system, with the N-Aβcore triggering a 
relatively brief transient peak compared to the longer sustained Ca2+ enhancement 
induced by Aβ, consistent with previous findings [146, 284].  Additionally, studies have 
shown that Aβ plays a role in disrupting Ca2+ homeostasis by altering the activity of 
calcium conducting ion channels, including, notably, NMDA-type glutamate receptors 
[291, 292], and dramatically increasing IP3-mediated Ca2+ release [293].  The variation in 
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Ca2+ responses may have been the result of differences in coupling to intracellular Ca2+, 
consequently activating different pathways and thus causing a unique signaling cascade 
for each N-terminal peptide.  It may also be that the differences resulted in part from 
differences in nAChR inactivation; however, this would best be assessed through ionic 
current measurements. Nonetheless, the differential cellular responses to the N-Aβcore 
and the N-Aβ fragment may account for the lack of neurotoxicity by these peptides.   
The underlying molecular mechanism(s) responsible for the prolonged increase in 
intracellular Ca2+ caused by the neurotoxic actions of Aβ may be a homeostatic failure.  
Considerable evidence supports a link between mitochondrial damage and dysfunction 
triggered by Ca2+ dysregulation occuring early on in the disease.  Changes in 
mitochondria function [26], morphology [25, 136], and dynamics [25, 294] resulting from 
the pathological effects of Aβ have been reported, with changes in mitochondrial 
bioenergetics dependent on decoding Ca2+ signals [295]. Here, we show that just one 
day of sustained Aβ exposure was enough to affect the mitochondrial membrane potential 
in our model system. Ca2+ homeostasis in the mitochondria is dependent upon the 
mitochondrial membrane potential, and, conversely, pathologically high levels of 
mitochondrial Ca2+ will collapse the membrane, resulting in an efflux of Ca2+ triggering a 
cell-death signaling cascade [296]. Interestingly, treatment with the N-Aβcore prevents 
the inactivation of the membrane potential by Aβ1-42, further suggesting that the transient 
Ca2+ response elicited by the N-Aβcore favors an alternative non-toxic pathway. 
Moreover, post-treatment with the N-Aβcore attenuated the Aβ1-42-triggered prolonged 
increase in intracellular calcium, further supporting its neuroprotective action against 
calcium dysregulation leading to mitochondrial dysfunction. 
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 As we had previously shown that that the N-Aβ fragment enhances synaptic 
regulation and fear memory, while reversing Aβ-linked inhibition of LTP [62], we 
subsequently addressed whether the N-Aβ fragment and N-Aβcore were capable of 
protecting against Aβ1-42-induced neuronal toxicity in vitro.  Continuous co-treatment with 
the N-Aβcore effectively and potently protected against Aβ1-42 -induced oxidative stress 
and apoptosis. Remarkably, treatment with the N-Aβcore after the induction of oxidative 
stress by Aβ1-42 also rescued the cells from this neurotoxicity. Furthermore, the fragment 
or N-Aβcore were also protective against neurotoxicity induced by high concentrations of 
Aβ1-42 in the absence of sensitizing nAChRs [136], again either with co-treatment or post-
treatment rescue.  Together, these findings suggest that the N-Aβ fragment and N-Aβcore 
may be neuroprotective through altered binding of Aβ1-42 for key target sites and/or 
activation of alternative pathways, such as an anti-apoptotic pathway and/or anti-oxidative 
pathway, blocking or reversing the process by which Aβ1-42 induces neurotoxicity. 
Consistent with previous findings [297], we found the histidine residues in the N-
terminal peptides to also be of essential importance in neuroprotection, indicating a 
necessary role in interaction with target Aβ receptors.  While the N-Aβcore was found to 
dock into the ligand binding site of the nAChRs [61], it will be important to examine the 
nature of the interaction of the N-Aβcore with other Aβ target receptors, including, in 
particular, cellular prion and NMDA receptors. On the other hand, the rescue by the N-
Aβcore (and N-Aβ fragment) long after initiation of the toxicity program by full-length Aβ 
would strongly suggest that the neuroprotective action of these peptides in cellular 
toxicity, and potentially synaptic and behavioral dysfunction, also includes altered 
intracellular signaling. 
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As a first approach to N-Aβcore modification as a means to reduce proteolysis of 
the hexapeptide in vivo, a dually N-terminus acetylated and C-terminus amidated analog 
(termed “capped” N-Aβcore) was synthesized and tested for neuromodulatory and 
neuroprotective activities, both of which were retained with the capped version. Additional 
stabilization of the N-Aβcore by converting each amino acid in the sequence from the L-
enantiomer to the D-enantiomer also, surprisingly, retained receptor activity.  Although 
the direct impact of enantiomeric conversion on interaction with target receptors remains 
to be determined, it has been shown that short synthetic D-amino acid peptides are 
capable of mimicking L-amino acid counterparts in binding to and activating target 
receptors [298] as well as antagonizing them [e.g. [299], suggesting that ligand chirality 
does not necessarily affect the binding specificity of some receptors, unlike that expected 
for enzymes. To assess the issue directly, it would be important to understand how the 
receptor interacts with the peptide’s side chains and backbone. Considering the evidence 
for a lack of enantiomer discrimination, we postulate that the N-Aβcore interaction with 
the target receptor is independent of the peptide backbone, but rather its side chains, 
particularly the aromatic rings of the two histidines, are key and may interact with the 
receptor in more than one orientation. This possibility may be addressed via molecular 
modeling. In addition, that the N-Aβcore analogs are actually stabilized against 
proteolysis may be assessed using a serum stabilization assay (see [300]). 
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CHAPTER 3: CHARACTERIZING THE NEUROPROTECTIVE EFFECTS 
OF THE N-AβCORE ON Aβ-INDUCED SYNAPTIC DYSFUNCTION AND 
ELUCIDATING THE NEUROPROTECTIVE PATHWAY OF THE N-AβCORE 
 
3.1 Introduction 
 AD is clinically characterized by changes in behavior and impairments in cognitive 
memory and function. Loss of critical pre- and post-synaptic markers have been reported 
for postmortem AD brain tissue [30, 301], suggesting that AD-related cognitive 
impairments are based, in large part, to synaptic dysfunction and loss.  Synapses are 
important for cell-to-cell communication and are typically damaged in neurodegenerative 
disease.  Additionally, accumulating evidence shows a strong link between excess 
soluble oligomeric Aβ and synaptic dysfunction in AD [20, 21, 145].  Cognitive decline 
and synaptic plasticity deficits are reported to occur prior to the accumulation of Aβ 
plaques and tau neurofibrillary tangles [302], supporting the idea that synaptic dysfunction 
and mild cognitive impairment are early events driven by soluble oligomeric Aβ rising to 
abnormally high levels years prior to AD diagnosis. Subsequent accumulation of plaques, 
and particularly, neurofibrillary tangles correlates with actual synapse and neuron loss. 
 Synaptic degeneration and dysfunction leads to abnormal synaptic transmission 
and impaired long-term potentiation (LTP) and/or long-term depression (LTD), which are 
important in synaptic plasticity and learning and memory paradigms.  Pathological levels 
(high nM to μM) of Aβ have been shown to inhibit LTP-induction [20, 303, 304] and 
enhance LTD [305, 306] in the hippocampus.  On the other hand, low physiological levels 
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(pM) of Aβ was found to enhance LTP and memory, indicating a hormetic effect of Aβ on 
synaptic plasticity [32, 307].   
NMDA-type and AMPA-type glutamate receptor activation plays an essential role 
in inducing LTP or LTD, depending on the levels of free cytosolic Ca2+ and its activation 
of downstream pathways [308]. Both NMDA and AMPA receptors are ionotropic and are 
permeable to Na+, K+, and, to varying degrees, Ca2+. Although they have distinct 
physiological properties, they often coexist at the same synapse.  Activation of GluR2-
containing AMPA receptors induces a strong influx of Na+ and a small efflux of K+, the net 
effect being depolarization of the postsynaptic neuron. Stimulation at the presynaptic 
neuron releases glutamate that binds to both NMDA and AMPA receptors on the 
postsynaptic side, but only AMPA receptors are activated during a weak stimulation 
resulting in a small depolarization (-35mV). At the resting membrane potential (-70mV) or 
during a weak depolarization, very few ions flow through the NMDA receptors, due to a 
magnesium block of the ion pore, and under these conditions, the field excitatory post-
synaptic potentials (fEPSPs) are solely due to AMPA receptor activation. Alternatively, 
with a strong stimulation, AMPA receptors can efficiently depolarize the postsynaptic 
membrane, which, in turn, dispels the magnesium block, allowing for the influx of Na+ and 
Ca2+ through the NMDA receptor, and subsequently, activation of various Ca2+-
dependent signaling cascades that are responsible for inducing long-term synaptic 
changes.   
Proper functioning NMDA and AMPA receptors are crucial for learning and 
memory, whereas improper activation can exacerbate AD pathogenesis.  In addition to 
mediating Aβ-induced excitotoxicity, as previously mentioned, NMDA-evoked currents 
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can be depressed by Aβ (at high concentrations)[309], inducing LTD [144], as 
consequence of subsequent downstream AMPA receptor internalization [144], 
desensitization [310], and dendritic spine loss.    
 One of the most studied mechanisms but not the sole mechanism of LTP induction 
is the activation of CaMKII.  In short, the influx of Ca2+ binds to calmodulin, which then 
binds to and activates CaMKII.  This ultimately leads to the phosphorylation of various 
proteins, including AMPA receptors [311], and subsequently, an increase in conductance 
[312]. Additionally, CaMKII-mediated phosphorylation of AMPA receptors promotes 
translocation of AMPA receptors to the postsynaptic membrane [313].  On the other hand, 
LTD involves the activation of protein phosphatases, such as calcineurin and protein 
phosphatase 1(PP1) [231].  Although the exact mechanisms of LTD are not as well 
understood, it is believed to be influenced by AMPA receptor dephosphorylation and 
internalization [144].     
The cAMP response element-binding protein (CREB) is an important transcription 
factor in mediating memory consolidation and LTP induction [314], neuronal survival [101] 
and neuroprotection [147].  Additionally, CREB is believed to upregulate the brain-derived 
neurotrophic factor (BDNF), which is important in modulating synaptic plasticity [148], and 
a neurotrophin target receptor, the tropomyosin receptor kinase receptor B (TrkB) [149], 
to promote cell survival.  Alternatively, under pathological conditions, CREB has been 
shown to be downregulated in hippocampal neurons in AD models [105], thus affecting 
synaptic plasticity and memory formation.     
All MAPK pathways, i.e. c-Jun N-terminal kinases (JNKs), extracellular signal 
regulated protein kinases (ERKs) and p38 have been implicated in Aβ pathogenesis [136, 
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256]: mediating tau hyperphosphorylation [315, 316], inducing apoptosis [317, 318], and 
activating γ- and β-secretases [319, 320]. Importantly, the ERK cascade has also been 
shown to play a role in learning and memory [242, 321] by activating important 
transcription factors implicated in synaptic plasticity [322], upregulating the translation of 
proteins associated with LTP [323], and increasing AMPA receptor insertion into 
postsynaptic membrane [324].  The exact mechanism in which Aβ induces LTP deficits 
is not well understood, but studies have indicated a potential link of the activation of 
certain kinases, specifically JNK and p38, to Aβ-induced LTP and synaptic dysfunction 
[244, 325].  
We have shown that at low concentration (pM-nM) the N-terminal Aβ fragment 
comprising amino acids 1-15/16 (N-Aβ fragment) is nearly twice as effective as full-length 
Aβ as a neuromodulator, stimulating receptor-linked increases in neuronal Ca2+, 
enhancing synaptic plasticity and enhancing contextual fear memory [62].  Considering 
the evidence that the N-Aβcore is the active region of the N-Aβ fragment, we aimed to 
better understand the neuroprotective mechanism of the N-Aβcore on synaptic plasticity.  
We assessed whether the N-Aβcore could rescue LTP and LTD dysfunction resulting 
from prolonged, elevated levels of Aβ, while aiming to elucidate the neuroprotective 
mechanism of the N-Aβcore against Aβ-neurotoxicity and synaptic deficits.   
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3.2 Methods 
3.2.1 Animals 
All animal handling, surgery, use and euthanasia were performed under an 
approved IACUC protocol (11-1219-6 or 16-2282-2), compliant with NIH and Society for 
Neuroscience guidelines for use of vertebrate animals in neuroscience research. The 
human APP/PSEN1 mouse line, 5XFAD (Tg6799), on the B6.SJL background (B6SJL-
Tg(APPSwFlLOn,PSEN1*M146L*L286V) 6799Vas/Mmjax; obtained from JAX stock 
#006554, MMRRC034840 Hemizygous) was used as a well characterized model for Aβ-
based pathology and neurodegeneration [326], along with age-matched control (B6.SJL 
background) mice (MMRRC034840 Non-carrier).  Mice at 7- to 8-months of age of both 
sexes (weight range: 28-35 g), originally housed in ventilated enrichment cages in the 
John A. Burns School of Medicine AAALAC-accredited Vivarium with ad libitum access 
to food and water, were used in roughly equal numbers, this age range selected for 
displaying pronounced LTP deficits in the transgenic line. Inclusion/exclusion criteria were 
based on animal health.  
 
3.2.2 Extracellular field potential recordings in hippocampal slices 
 Hippocampal slices were prepared from 7- to 8- month-old 5XFAD (Tg6799) or 
B6.SJL (control mice).  Cervical dislocation and decapitation were performed under an 
approved IACUC protocol (11-1219-6 or 16-2282-2).  Brains were extracted into ice-cold 
artificial cerebral spinal fluid (aCSF) consisting of 130 mM NaCl, 3.5 mM KCl, 10 mM 
glucose, 1.25 mM NaH2PO4, 2.0 mM CaCl2, 1.5 mM MgSO4, and 24 mM NaHCO3, 
bubbled with 95% O2/5% CO2.  Transverse brain slices of 400μm were obtained using a 
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Leica vibrating microtome (Leica, VT1200S) and quickly transferred to fresh ice-cold 
aCSF for hippocampi isolation.  Extracted hippocampi slices were incubated in bubbled 
aCSF in a holding chamber for 30 min at room temperature (23°C) after which the holding 
chamber was transferred to a 32°C water bath for 1 h.  The chamber was then removed 
from the water bath and placed at room temperature for another 1 h prior to recording. 
The slices were subsequently transferred to a recording chamber and perfused at 
3mL/min with aCSF (bubbled with 95% O2/5% CO2) at 32°C.  The Schaffer collateral 
fibers were stimulated at a frequency 0.1 Hz using a bipolar stimulating electrode and 
CA1 field excitatory postsynaptic potentials (fEPSPs) were recorded with a glass 
electrode filled with 3M NaCl (resistance 1-1.5 MΩ).  Basal synaptic transmission was 
assessed by comparing stimulus strength against fEPSP slope to generate input/output 
(I/O) curves.  In the following experiments, a minimum of 20 min baseline stimulation was 
performed, recording every minute.  The baseline and stimulus current were adjusted 
during this period so that fEPSP stabilized at 30-40% of maximum.  
 LTP was induced by a 3-theta-burst stimulation (TBS) protocol, where each burst 
consisted of 4 pulses at 100 Hz with a 200-ms interburst interval.  LTD was induced using 
a low frequency stimulation (LFS) protocol, consisting of a 1Hz single pulse stimulus (900 
pulses for 15 min).  TBS and LFS were administered after a 20-min baseline recording 
period for aCSF alone or a 35-min baseline recording period for aCSF (15 min) followed 
by N-Aβcore (20 min).  Importantly, TBS and LFS were administered in the presence of 
the N-Aβcore for treatment experiments.   
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3.2.3 Protein extraction 
 NG108-15 cells were cultured as described in section 2.2.1.  The NG108-15 cells 
were allowed to grow to 80% confluency in a 25 cm2 flask prior to differentiation 
(described in section 2.2.1) and subsequent transfection (described in section 2.2.1) 72 
h later.  Forty-eight hours after transfection, NG108-15 cultures were subjected to various 
treatments for three days. The medium for each treatment condition was changed every 
day, unless otherwise noted.   
 For protein extraction, the cells were washed with cold 1x phosphate-buffered 
saline (PBS) and lysed with 200 µL of 1% SDS (Fisher Scientific, catalog # BP166-100, 
lot 122975). The lysates were frozen at 20°C and immediately transferred to a 95°C 
heating block for 5-10 min, followed by sonication for 15-20 min to shear the DNA.  The 
total amount of protein was quantified by a Pierce™ BCA Protein Assay Kit 
(ThermoFisher Scientific, catalog # 23225).   
 
3.2.4 Western blot 
 Gel sample buffer (4x; ThermoFisher Scientific, catalog # B0007, lot # 1549819) 
and reducing agent (10x; ThermoFisher Scientific, catalog # B0009, lot # 1901009) were 
added to diluted SDS-solubilized protein samples for a final protein concentration of  1 
µg/µL. The samples were boiled to 95°C for 5 min, immediately cooled on ice and then 
centrifuged.  Equal amounts of protein were subjected to electrophoretic separation on a 
4-20% Tris-Glycine polyacrylamide gel (ThermoFisher Scientific, catalog XP04200), 
transferred to an activated PVDF membrane (“blot”; Millipore, catalog # IPFL00010) for 2 
h at 50 V, and incubated in primary antibody overnight at 4°C.  Blots were washed 3x (5 
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min each wash) in 0.1% Tween-20 in TBS (Tris Buffered Saline) and incubated in the 
appropriate IR-dye conjugated secondary antibody (LI-COR Biosciences, Lincoln, NE) for 
1h. An Odyssey IR imaging system (LI-COR Biosciences, Lincoln, NE) was used for 
detection and analysis was performed via Image Studio v4.0 software (LI-COR 
Biosciences, Lincoln, NE).  
 
3.2.3 Antibodies 
 The following primary antibodies were used for detection. Rabbit anti-phospho 
CREB at 1:1000 dilution (Cell Signaling, catalog # 9198S, lot 14), rabbit anti-CREB at 
1:1000 dilution (Cell Signaling, catalog # 9197S, lot 16), rabbit anti-phospho PERK at 
1:1000 dilution (Cell Signaling, catalog # 3179S), rabbit anti-PERK at 1:1000 dilution (Cell 
Signaling, catalog #3192S), mouse anti-phospho JNK at 1:500 dilution (Santa Cruz 
Biotechnology, catalog # 6254, lot G0711), rabbit anti-SAPK/JNK at 1:1000 dilution (Cell 
Signaling, catalog # 9252S, lot 16), rabbit anti-phospho p44/42 MAPK at 1:1000 dilution 
(Cell Signaling, catalog # 4370S, lot 12), mouse anti-p44/42 MAPK at 1:1000 dilution (Cell 
Signaling, catalog # 4696S, lot 21), mouse anti-β-actin at 1:2000 dilution (Sigma Aldrich, 
catalog # A2228, lot 112M4762V), and mouse anti-β-tubulin at 1:1000 dilution (Cell 
Signaling, catalog # 86298S, lot 1). 
 
3.2.4 Reactive Oxygen Species (ROS)/ Hoechst staining 
 See section 2.2.4. 
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3.2.5 Statistical analysis 
 Treatment and units were randomized as to order for all assays and experiments. 
Biological replicates were based on independent samples (n). All experiments were 
repeated at least three times unless otherwise noted.  Multiple comparisons were made 
using one-way ANOVA with Bonferroni or Tukey post hoc tests, as indicated. Paired 
comparison was made using Student’s t-tests. P-values <0.05 were considered the 
minimum for significance (as rejection of the null hypothesis). Unless otherwise noted, 
data were analyzed and graphed with GraphPad Prism 5 (GraphPad v5.0b; 
RRID:SCR_002798) using the appropriate statistical tests.  
 
3.3 Results 
3.3.1 The N-Aβcore protects against LTP deficits induced by pathological levels of 
full-length Aβ 
 We have previously shown that the N-Aβ fragment enhances synaptic plasticity 
and contextual fear memory while protecting against Aβ-linked synaptic impairment [62]. 
Considering the evidence that the N-Aβcore accounts for the neuromodulatory activity of 
the N-Aβ fragment, we assessed whether the N-Aβcore is capable of protecting against 
Aβ-induced synaptic dysfunction ex vivo.  We utilized hippocampal slices from our APP 
(Aβ) mouse model (5xFAD) and their wild-type counterparts (B6.SJL) to examine synaptic 
transmission.  Basal synaptic transmission at the Schaffer collateral-CA1 synapses 
(input-output curve) shows that the fEPSP slopes versus stimulus strength for both the 
5xFAD and B6.SJL mice were comparable (Fig. 12A), ruling out any issues with regard 
to baseline synaptic strengths.  Interestingly, treatment with the N-Aβcore during baseline 
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recordings shows an increase in baseline synaptic transmissions for both 5xFAD and 
B6.SJL but was only significant in the B6.SJL slices (Fig. 12B). To assess sustained 
changes in synaptic plasticity, we used a 3x TBS stimulation protocol at the Schaffer 
collaterals to measure LTP (see cross-sectional cartoon of the hippocampus in Fig. 12A, 
inset).  LTP showed a trend toward enhancement for the N-Aβcore-treated B6.SJL slices, 
though it was not significant (Fig. 12C). Consistent with previous findings, LTP in the 
5xFAD slices was substantially reduced compared to that observed for slices from B6.SJL 
[327] (Fig. 12C), dropping to near baseline at 60 min post-TBS.  By contrast, treatment 
with 500nM N-Aβcore restored LTP in the 5xFAD slices to the level seen for the wild-type 
slices (Fig. 12C and 12D).  These findings demonstrate that the N-Aβcore can reverse 
LTP deficits induced from prolonged exposure to pathological levels of Aβ, while 
enhancing basal synaptic transmission.  
 Through a receptor-linked Ca2+ assay, we have shown that mutating the tyrosine 
residue in the N-Aβcore to a serine [Y10S] or mutating the two histidine residues to two 
alanines [H13A,H14A] reduces activity (Fig. 4), indicating these amino acid residues in 
the N-Aβcore sequence are essential for activity.  As a control, we assessed synaptic 
changes with the reverse N-Aβcore [QHHVEY] and a triple (inactive) mutant [SEVAAQ] 
on LTP in 5xFAD hippocampal slices. Surprisingly, treatment with the reverse N-Aβcore 
potentiated LTP in the 5xFAD hippocampal slices (Figs. 13A and 13B).  By contrast, the 
inactive triple mutant had no effect on synaptic potentiation in the 5xFAD slices (Figs. 13A 
and 13B).  It is important to note that we did not see an increase in basal synaptic 
transmission or a trend toward increasing LTP in the wild-type slices with the reverse N-
Aβcore, as seen for the N-Aβcore (Fig. 12).  Taken together, these results suggest that 
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the two histidine residues, in particular, contribute to the strong positive neuromodulatory 
activity of the N-Aβcore. 
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Figure 12: The N-Aβcore protects against Aβ-induced synaptic impairments 
Sustained changes on synaptic plasticity by a 3x-TBS protocol.  A, Input/Output curve plotting 
fEPSP slopes verses stimulus strength before treatment.  B, Baseline recordings prior to 
stimulation treated with control aCSF in 5xFAD (red, n=4) and B6.SJL (black, n=5) or 500nM N-
Aβcore in 5xFAD (blue, n=4) and B6.SJL (grey, n=3).  C, TBS-induced LTP, with color-coded 
inserts showing examples of fEPSP for B6.SJL perfused with control aCSF (black, n=5) or 500nM 
N-Aβcore (grey, n=3) and 5xFAD with aCSF (red, n=4) or 500nM N-Aβcore (blue, n=4).  D, 
Average fEPSP slope values for 50-60 min post-tetanus.  n refers to the number of slices.  Data 
are means ± S.E.M.  C, inset calibration: horizontal, 10ms; vertical, 0.4 mV.  *p<0.05 (Bonferroni 
post hoc tests for comparison with 5xFAD aCSF treatment (red)). 
Figure 13: The reverse N-Aβcore and inactive triple mutant on LTP 
Sustained changes on synaptic plasticity by a 3x TBS protocol.  A, TBS-induced LTP, with control 
input/output and color-coded inserts showing examples of fEPSP for B6.SJL perfused with control 
aCSF (black, n=5) and 5xFAD with aCSF (red, n=4), 500nM [SEVAAQ] (grey, n=5) or 500nM 
[QHHVEY] (blue, n=3).  B, Average fEPSP slope values for 50-60 min post-tetanus.  n refers to the 
number of slices.  Data are means ± S.E.M.  A, inset calibration: horizontal, 10ms; vertical, 0.4 mV.  
*p<0.05 (Bonferroni post hoc tests for comparison with B6.SJL aCSF treatment (black)). 
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    We further examined different concentrations of the N-Aβcore on reversing Aβ-
induced LTP deficits.  As compared to the nM concentration of the N-Aβcore used 
previously (Figs. 12 and 13), low concentrations (fM) of the N-Aβcore showed no 
difference on LTP compared to control 5xFAD slices (Figs. 14A and 14B).  These data 
indicate that the reversal of Aβ-induced synaptic dysfunction by the N-Aβcore is 
concentration-dependent.  We therefore postulate that the rescue of Aβ-linked LTP 
deficits by the N-Aβcore will fall within the range of fM and nM. 
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3.3.2 Elevated levels of Aβ enhances long-term depression and the N-Aβcore 
reverses Aβ-induced LTD enhancement 
 
 Another important aspect of synaptic plasticity is LTD and to date, very few studies 
have examined the effects of pathological levels of soluble Aβ on LTD induction, and 
moreover, the results have been inconsistent.  For example, focusing on NMDA receptor-
dependent LTD, the administration of synthetic Aβ resulted in an enhancement of LTD 
[306, 328] whereas similar studies conducted by other groups show no effect [329].  Here 
we aimed to examine the effects of endogenous soluble Aβ on LTD.  Using LFS to induce 
LTD in the Schaffer collateral – CA1 pathway, LTD in slices from 5xFAD mice was 
significantly enhanced compared to that observed for LTD induced in slices from B6.SJL 
control mice (Figs. 15A and 15B).  Interestingly, treatment with the N-Aβcore prior to and 
during LFS resulted in a near-complete rescue of LTD in the 5xFAD mouse slices (Figs. 
15A and 15B).  Taken together, these data suggest that Aβ plays a role in facilitating LTD 
and the N-Aβcore may protect against Aβ-induced LTD enhancement.  The role of the 
NMDA receptor on Aβ facilitation of LTD warrants further investigation.   
 
Figure 14: The N-Aβcore protection of Aβ-induced synaptic dysfunction is concentration 
dependent 
Sustained changes on synaptic plasticity by a 3x TBS protocol.  A TBS-induced LTP, with control 
input/output and color-coded inserts showing examples of fEPSP for B6.SJL perfused with control 
aCSF (black, n=5) and 5xFAD with aCSF (red, n=4), 500fM N-Aβcore (dark blue, n=3) or 500nM 
N-Aβcore (light blue, n=4).  B Average fEPSP slope values for 50-60 min post-tetanus.  n refers 
to the number of slices.  Data are means ± S.E.M.  Calibration: horizontal, 10ms; vertical, 0.4 mV.  
*p<0.05 (Bonferroni post hoc tests for comparison with 5xFAD aCSF treatment (red)). 
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Figure 15: The N-Aβcore reverses endogenous Aβ enhancement of LTD  
Sustained changes in synaptic plasticity by a 1Hz LFS protocol.  A, LFS-induced LTD, with control 
input/output and color-coded inserts showing examples of fEPSP for B6.SJL perfused with control 
aCSF (black, n=3) and 5xFAD with aCSF (red, n=3), or 500nM N-Aβcore (blue, n=4).  B, Average 
fEPSP slope values for 50-60 min post-tetanus.  n refers to the number of slices.  Data are means 
± S.E.M.  Inset scale calibration: horizontal, 10ms; vertical, 0.4 mV.  *p<0.05 (Bonferroni post hoc 
tests for comparison with B6.SJL aCSF treatment (black)). 
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3.3.3 The N-Aβcore rescues Aβ-induced activation of cellular stress markers ERK 
and JNK 
 We have previously shown that prolonged exposure to nanomolar levels of Aβ 
activates various stress markers in the MAPK pathway while in the presence of the 
sensitizing α4β2-nAChRs in vitro [136].  In accordance with our previous studies, we show 
an increase in phosphorylation of ERK and JNK, indicative of activation (Figs. 16 and 17, 
respectively) upon nM treatment with Aβ in α4β2-nAChR-transfected NG108-15 cell 
cultures.  Furthermore, treatment with varying concentrations of the N-Aβcore (pM and 
nM) trended towards a reduction in phosphorylation of ERK and JNK (Figs. 16 and 17, 
respectively). Surprisingly, pM concentrations of the N-Aβcore inhibits phosphorylation of 
JNK to below baseline levels (Fig. 17), suggesting an unusual concentration-dependent 
mechanism for N-Aβcore activity.   
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Figure 16: The N-Aβcore rescues Aβ activation of ERK 
Western blot of total and phospho-ERK in protein extracts from nAChR-expressing NG108-15 
cells treated with N-Aβcore, Aβ or both. (Top) Representative western immunoblot image 
showing levels of phopho-ERK1 and phopho-ERK2, total ERK1 and total ERK2, and actin 
(loading control).  (Bottom) Quantification of the expression of pERK1 and pERK2 normalized to 
total ERK, after adjusted for protein loading. Treatment concentrations were 100pM or 100nM. 
n=3, n refers to number of replicates.  Data are means ± S.E.M.    
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Figure 17: The N-Aβcore rescues Aβ activation of JNK 
Western blot of total and phospho-JNK in protein extracts from nAChR-expressing NG108-15 
cells treated with N-Aβcore, Aβ or both. (Top) Representative western immunoblot image 
showing levels of phopho-JNK1 and phopho-JNK2,3, total JNK1 and total JNK1,2, and actin 
(loading control).  (Bottom) Quantification of the expression of pJNK1 normalized to total JNK 
after adjusting for protein load Treatment concentrations were 100pM or 100nM. n=3, n refers 
to number of replicates.  Data are means ± S.E.M. *p<0.05, **p<0.005 (Tukey post hoc tests 
for comparison)  
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Next, we assessed whether the reduction of Aβ-induced ERK and JNK activation 
on treatment with the N-Aβcore was specific to α4β2-nAChRs.  In the absence of α4β2-
nAChRs, we found that µM concentrations of Aβ are necessary to activate ERK and JNK 
to above baseline levels (Figs. 18 and 19, respectively).  While treatment with nM-µM N-
Aβcore did not seem to reduce Aβ-induced ERK activation (Fig. 18), preliminary 
experiments treatment with the N-Aβcore showed a trend towards a reduction in Aβ-
induced JNK activation independent of nAChRs (Fig. 19).   
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Figure 18: Aβ-induced activation of ERK in the absence of nAChRs 
Western blot of total and phospho-ERK in protein extracts from nAChR-expressing NG108-15 cells 
treated with N-Aβcore, Aβ or both. (Top) Representative western immunoblot image showing levels 
of phopho-ERK1 and phopho-ERK2, total ERK1 and total ERK2, and control actin.  (Bottom) 
Quantification of the expression of pERK1 and pERK2 normalized to total ERK. n=3, n refers to 
number of replicates.  Data are means ± S.E.M.    
 
 
Figure 19: Aβ-induced activation of JNK in the absence of nAChRs 
Western blot of JNK in protein extracts from nAChR-expressing NG108-15 cells treated with 
N-Aβcore, Aβ or both. (Top) Representative western immunoblot image showing levels of 
phopho-JNK1 and phopho-JNK2,3, total JNK1 and total JNK1,2, and control actin.  (Bottom) 
Quantification of the expression of pJNK1 normalized to total JNK. Treatment concentrations 
were 100pM or 100nM. n=2, n refers to number of replicates.  
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Together these preliminary data indicate that the N-Aβcore may be able to protect 
against Aβ activation of the stress kinase JNK in both nicotinic receptor-expressing and 
control cells, whereas the reduction of ERK activation by the N-Aβcore appears to be 
nAChR-dependent.    
 
3.3.4 Picomolar concentration of the N-Aβcore reduces reactive oxygen species 
levels to below baseline 
 Our surprising, yet interesting findings that pM levels of the N-Aβcore inhibits JNK 
activation (Fig. 17) prompted us to investigate oxidative stress at low N-Aβcore 
concentrations.  In preliminary experiments in the presence of α4β2-nAChRs, pM 
Figure 20: The N-Aβcore reduces oxidative stress levels to below baseline 
A, Representative images of Hoechst and ROS staining of differentiated NG108-15 cells 
expressing nAChRs.  B, Treatment with treatment with pM-nM N-Aβcore with 100nM Aβ1-42 in the 
presence α4β2-nAChR (n=2). n refers to number of replicates 
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concentrations of the N-Aβcore not only protected against the Aβ-induced oxidative 
stress, but also reduced ROS levels to below baseline (Fig. 20). These data suggest that 
the extent of neuroprotective activity of the N-Aβcore also displays an unusual 
concentration-dependence and that the N-Aβcore may be eliciting an Aβ-independent, 
alternative neuroprotective pathway.   
Figure 21: Low levels of the N-Aβcore upregulates CREB activity and expression 
Western blot of total and phospho-CREB in protein extracts from nAChR-expressing NG108-15 
cells treated with N-Aβcore, Aβ or both treatments. A, Representative western immunoblot image 
showing levels of pCREB, total CREB and control β-tubulin. B, Quantification of the expression 
of pCREB normalized to β-tubulin. C, Quantification of the expression of total CREB normalized 
to β-tubulin. Treatment concentrations were 100pM or 100nM. n=2, n refers to number of 
replicates.  
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3.3.5  Picomolar concentrations of N-Aβcore upregulates phospho-CREB and total 
CREB 
 CREB is an important transcription factor implicated in cell survival and 
proliferation as well as synaptic modulation for learning and memory (see sections 1.3.5 
and 1.4.5).  To better understand the neuroprotective mechanism of the N-Aβcore on cell 
survival and synaptic plasticity, we investigated whether the N-Aβcore affected CREB 
activation and expression. We found in preliminary experiments that the results with 
treatment with Aβ suggested a trend towards a reduction in phospho-CREB (Fig. 21B) 
but had no effect on total CREB levels (Fig. 21C). It is unclear whether this reduction is 
due solely to the presence of α4β2-nAChRs and thus warrants further investigation.  
Additionally, treatment with 100nM N-Aβcore showed no difference in the activation or 
expression of CREB compared to untreated control in both α4β2-nAChR- and mock-
transfected cells (Figs. 21B and 21C) nor did it trend towards a reversal of the Aβ effect 
on phospho-CREB (Figs 21B).  Interestingly, 100pM N-Aβcore upregulated CREB activity 
and expression in an α4β2-nAChR-dependent manner even in the presence of Aβ (Figs. 
21B and 21C), suggesting that the N-Aβcore can directly stimulate activity.  Consistent 
with our earlier findings, we believe that the N-Aβcore’s neuroprotective action is 
dependent on concentration, where pM levels of the N-Aβcore have shown to be most 
effective.  These data are generally consistent with the idea that the N-Aβcore activates 
an Aβ-independent neuroprotective pathway.   
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3.3.6 The N-Aβcore reduces Aβ-induced ER stress 
 Detrimental levels of Aβ induces cellular stress that effects Ca2+ homeostasis in 
the endoplasmic reticulum (ER).  This further causes ER stress which, in turn, induces 
the accumulation of unfolded proteins, eliciting the unfold protein response (UPR) and 
activates the ER-stress-induced apoptotic pathway [330]. There is additional evidence 
implicating ER stress in the neuronal death that occurs in AD [331, 332].  Here, we aimed 
to address whether the N-Aβcore can protect against Aβ-induced ER stress.  We 
examined a protein kinase-like endoplasmic reticulum kinase (PERK) as an ER stress 
marker. Activation of PERK via phosphorylation couples ER stress to inhibition of protein 
translation [333].  Treatment with nM Aβ activates PERK in α4β2-nAChR-transfected cells 
(Fig. 22).  Additionally, in preliminary experiments pM-nM N-Aβcore reduced Aβ activation 
of PERK (Fig. 22), suggesting that the N-Aβcore can protect against Aβ-induced ER 
stress.   
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Figure 22: Aβ-induced activation of PERK in nACHR-transfected cells 
Western blot of PERK in protein extracts from nAChR-expressing NG108-15 cells treated with N-
Aβcore, Aβ or both. (Top) Representative western immunoblot image showing levels of pPERK, 
total PERK, and control actin.  (Bottom) Quantification of the expression of pPERK normalized to 
total PERK. Treatment concentrations were 100pM or 100nM. n=2, n refers to number of replicates.  
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3.4 Discussion  
Previous studies have established a strong link between the progression of AD 
and the extent of synaptic dysfunction occurring in the early stages of the disease, prior 
to the formation of Aβ plaques and tau neurofibrillary tangles [302].  While the exact 
mechanism of synaptic dysfunction and eventual loss is not well understood, evidence 
suggests that pathological levels of Aβ induces NMDA receptor-linked excitotoxicity, and 
this over-stimulation of NMDA receptors activates a cascade of pathological signaling 
which accounts for neuronal death and synaptic dysfunction [28, 29, 306] in AD.   
 
3.4.1 Impact of Aβ on LTP vs. LTD 
Two key mechanisms underlying synaptic plasticity and memory formation are LTP 
and LTD induction.  Although it is well determined that detrimental levels of soluble Aβ 
have been implicated in LTP inhibition [20, 303, 304], the link between pathological levels 
of Aβ and LTD are less understood, even showing conflicting results.  Alternatively, very 
low levels (pM) of soluble Aβ have been shown to enhance synaptic plasticity and 
facilitate hippocampal-based learning and memory [32], suggesting a neuromodulatory 
role of soluble Aβ at physiological levels. In addition, similar results using an N-terminal 
fragment of Aβ (1-15) implicated that sequence within Aβ as accountable for the positive 
neuromodulatory activity of full-length Aβ [62].  Thus, we wondered whether the N-Aβcore 
(10-15), encompassing the essential sequence within the N-terminal fragment, and be 
inference, Aβ for the positive neuromodulatory activity could enhance synaptic plasticity 
and protect against Aβ-induced synaptic dysfunction.   
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In accordance with previous findings [327], we found that pathological levels of 
endogenous soluble Aβ significantly inhibits LTP induction, but treatment with the N-
Aβcore reversed this deficit.  Although not significant, treatment with the N-Aβcore in wild-
type slices showed a trend towards LTP enhancement. This suggests that the protection 
against Aβ-induced LTP deficits by the N-Aβcore is not solely due to competitive binding 
for target receptors, but may also be in combination with the activation of a 
neuroprotective pathway that enhances synaptic plasticity.  The exact pathway that is 
activated is not yet known, but we suspect that key players involved in synaptic 
modulation are affected, such as upregulating CREB, PKA, and/or CAMKII or 
downregulating calcineurin and/or PP1, subsequently increasing AMPA receptor 
trafficking to the synapses [334, 335].  Additionally, the enhancement of the basal 
synaptic transmission with the treatment of the N-Aβcore in both 5xFAD and B6.SJL 
slices suggests a receptor-linked influx of Ca2+, which further supports the idea that the 
N-Aβcore activates an alternative neuroprotective pathway that enhances synaptic 
plasticity. Previously, it has been shown that BDNF enhances basal synaptic transmission 
[336], therefore, we suspect that the N-Aβcore may be upregulating BDNF expression, 
possibly through the increase in CREB activation and/or expression [148, 216].  Another 
possibility is that the N-Aβcore-induced Ca2+ influx could also be responsible for BDNF 
release at the synapses, thus, enhancing baseline synaptic transmission and ultimately 
LTP.  It would be interesting to examine the effect of the basal synaptic transmission by 
the N-Aβcore long-term to assess whether this is a transient or permanent increase, and 
whether the enhancement of LTP observed was due to the changes in baseline 
transmission. 
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Without a proper mechanism to selectively weaken the synapse after 
strengthening caused by LTP, no new information would be encoded due to a ceiling-
effect, and thus, LTD is necessary for neural homeostasis.  To date, there are conflicting 
studies about the effects of pathological Aβ on LTD, where some groups show that 
synthetic Aβ enhances LTD [306, 328, 337, 338] and others show no effect [329, 339].  
Here, we found that the presence of endogenous soluble Aβ, shown to be present in the 
brains of 5xFAD mice, resulted enhances LTD in isolated hippocampal slices, and 
treatment with the N-Aβcore prior to and during the LFS induction of LTD reverses this 
enhancement.  Interestingly, Hu et. al. found that applying synthetic soluble Aβ prior to 
LFS did not affect the early phase of LFS-induced LTD (<2h post LFS), but facilitated the 
late phase (3-5 h post LFS) [337], thus, possibly accounting for the reason why some 
groups did not report a difference. It is important to note that late phase LTP and LTD 
require new protein synthesis. Considering the fact that LTD and LTP work in concert to 
allow for reversible synaptic plasticity, the LFS-induced enhancement of LTD in the 
5xFAD slices could affect subsequent LTP, and this may be another reason why an LTP 
deficit was observed in the 5xFAD slices compared to wild-type.  
While, as noted, NMDA and AMPA receptors are involved in different aspects of 
LTP and LTD, and are affected by elevated Aβ, metabotropic glutamate receptors 
(mGluRs) have also been implicated in Aβ-induced synaptic dysfunction [244, 306, 338].  
It would therefore be interesting to further address the role of mGluRs in Aβ-linked 
synaptic deficits and the reversal these deficits by the N-Aβcore. 
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3.4.2 Intracellullar signaling pathways in Aβ-induced neurotoxicity and synaptic 
dysfunction  
Turning to intracellular signaling pathways, the activation of the MAPK pathway 
has been strongly implicated in Aβ-induced neurotoxicity and synaptic dysfunction [244, 
256, 340].  Specifically, we have shown that treatment with Aβ in the α4β2-nAChR-
transfected NG108-15 cells increased ERK and JNK activation (via phosphorylation) in 
the early stages of the apoptotic process, thus contributing to the Aβ-induced neuronal 
toxicity in our model [136].  Taken together with the fact that the N-Aβcore has been 
shown to protect against Aβ-induced apoptosis and synaptic deficits, we aimed to better 
understand the neuroprotective mechanism of the N-terminal fragments against Aβ-
toxicity, starting with its effect on the MAPK pathway.   
In accordance with our previous findings, Aβ increases activation of both ERK and 
JNK in the presence [136] and absence of the sensitizing nAChRs.  However, the 
reduction of Aβ activation of ERK by the N-Aβcore was found to be nAChR-dependent. 
This does not come at a complete surprise considering the evidence linking nAChRs to 
ERK activation [341–344] and downstream of that, CREB phosphorylation and 
translocation [344].  Thus, we postulate that the ERK-linked synaptic enhancement of the 
N-Aβcore is mediated by the nAChRs. 
 On the other hand, the reduction of Aβ-induced JNK activation by the N-Aβcore 
was found to be nAChR-independent, and more importantly, only pM concentration of the 
N-Aβcore inhibits JNK activation.  These data suggest that at lower concentrations the N-
Aβcore blocks apoptosis by inhibiting JNK activation.  The exact mechanism of this 
inhibition is currently not understood but we postulate that the N-Aβcore may upregulate 
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a JNK-specific phosphatase or inhibit JNK phosphorylation by modulating one of the 
scaffolding proteins. Furthermore, studies have shown that JNK1-deficient models have 
enhanced memory [345, 346], and therefore, we speculate that the inhibitory influence of 
the N-Aβcore on JNK phosphorylation contribute to the N-Aβcore LTP enhancement and 
protection against Aβ-induced LTP deficits.  The fact that this degree of inhibition was 
only observed at pM levels of the peptide suggests that high concentrations (nM) of the 
N-Aβcore may somehow be masking this action of pM N-Aβcore. Moreover, the reduction 
in oxidative stress to below baseline levels and upregulation of CREB activity and 
expression observed with pM N-Aβcore further supports our postulate that the N-Aβcore 
is eliciting an alternative neuroprotective pathway, and although still protective, nM 
concentrations of the N-Aβcore may be attenuating the effects seen at pM concentrations.   
Taken together, our results suggest a concentration-dependent neuroprotective 
action of the N-Aβcore on synaptic plasticity.  While the exact molecular pathway still 
remains to be elucidated, we postulate that the N-Aβcore binds to target receptors to 
modulate the expression of proteins involved in enhancing synaptic plasticity.      
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CHAPTER 4: CONCLUSION 
4.1 Final Remarks 
 A tremendous amount of effort in both scientific and clinical research has been 
focused on understanding and developing a cure for AD.  Unfortunately, many of the 
potential therapeutic agents have fallen short in clinical trials, resulting in only two classes 
of FDA-approved drugs for AD treatment on the market.  This is in part, due to the fact 
that AD is a multifactorial disorder that involves multiple biological pathways, and thus, 
targeting one pathway for treatment has proved to be unsuccessful.  In addition, soluble 
Aβ deposition and Aβ-toxicity occurs years before the onset of AD symptoms [278]. 
Therefore, it is imperative to begin treatment at the right window of opportunity to halt the 
progression of the disease and to preserve any existing neuronal and synaptic function.  
Furthermore, a disruption in Aβ’s normal physiological function could contribute to further 
toxicity [36].   
Previous studies have found Aβ monomers to be protective against oligomeric Aβ 
toxicity [128], but maintaining stable monomeric Aβ in vivo may be hard, if not impossible 
to achieve.  Alternatively, an N-terminal fragment of Aβ (1-15/16) naturally derived from 
Aβ by the action of α-secretase, which does not oligomerize, is not toxic and whose 
sequence was shown to be responsible for the neuromodulatory activity of full-length Aβ 
[62], may provide an entirely different means to approach AD therapy.  Here, we showed 
that a core hexapeptide sequence within this fragment (N-Aβcore), encompassing the 
key residues attributing to the neuromodulatory activity to the N-terminal fragment, was 
able to protect against Aβ-induced mitochondrial dysfunction, oxidative stress and 
apoptotic neuronal death, whether added as co-treatment or post Aβ treatment, as well 
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as rescue Aβ-induced LTP and LTD deficits in 5X FAD model mice.  It was further found 
that the N-Aβcore protects against Aβ toxicity involving high affinity Aβ receptors 
(nAChRs) as well as other low affinity Aβ target receptor(s), suggesting that the N-Aβcore 
may be broadly neuroprotective through altered interaction of Aβ with all key target sites 
and/or activation of alternative pathways, such as the aforementioned neuroprotective 
pathways, making it a highly effective neuroprotective agent against Aβ-linked neuronal 
toxicity, synaptic dysfunction, and behavioral deficits. Moreover, the peptide is small 
enough to provide a platform for small molecule peptidomimetic drug development. 
The precise mechanism by which the N-Aβcore exerts its effect(s) is still not fully 
understood, but from our findings, we postulate that the N-Aβcore acts as a competitive 
(partial) agonist binding to target receptors to (1) modulate Ca2+-dependent pathways, (2) 
the MAPK pathway and (3) elicit a signaling cascade to upregulate proteins to enhance 
cell survival and synaptic plasticity.  Direct demonstration that the N-Aβcore competitively 
blocks Aβ binding target receptors via ligand binding assays remains to be determined. 
However, we have previously shown that concurrent administration of both nanomolar N-
Aβ fragment and micromolar Aβ to cells expressing nAChRs resulted in a decrease in the 
Ca2+ response compared to Aβ alone [62], suggesting competition between the two. Here, 
we showed that late addition of the N-Aβcore after initiating Ca2+ responses with either 
the N-Aβ fragment or Aβ alone also sharply reduced the responses. Therefore, we 
suspect the N-Aβcore acts as a partial agonist to competitively antagonize Aβ binding to 
target receptors, attenuating Aβ-induced toxicity, and thus, partially contributing to the 
neuroprotection observed.  On the other hand, our results indicate that the N-Aβcore is 
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also elicits an alternative protective pathway that attenuates and/or inhibits Aβ toxicity 
(Fig. 23).   
Taken together, our data suggest that the small, nontoxic N-Aβcore not only 
protects against Aβ-induced neuronal and synaptic toxicity, but when administered at the 
later stages of the disease, would be capable of preserving cellular and synaptic function.  
In addition, we have shown that stabilization of the N-Aβcore retains functionality, 
therefore, providing a good platform for further drug development.  
 
Figure 23: Suggested neuroprotective action of the N-Aβcore against Aβ toxicity 
Although the exact pathway is still not fully identified, the N-Aβcore has been shown to protect 
against Aβ-induced ER-stress, mitochondrial dysfunction, oxidative stress and MAPK-linked 
apoptosis.  The synaptic enhancement by the N-Aβcore may be attributed to an increase in PKA 
and CaMKII activity, and thus, increasing CREB activity and possibly expression.  
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4.2 Future Directions 
 It is well established that Aβ interacts with numerous receptors [141]. In addition 
to the high-affinity nAChRs, two prominent targets linked to Aβ are the cellular prion 
protein (PrPc) and paired immunoglobulin-like receptor B (PirB) [347]. It will be important 
to address the specific role(s) for PrPc and/or PirB in the action of the N-Aβcore to protect 
against Aβ neurotoxicity and synaptic and behavioral dysfunction. 
 An intriguing finding in our studies is that pM concentrations of the N-Aβcore shows 
the most robust effect in reducing oxidative stress, blocking JNK activation and 
upregulating CREB activity and expression, indicating a highly potent action of the N-
Aβcore peptide. We have postulated that nM concentrations of the N-Aβcore, although 
still protective, attenuate or outright reverse the response at pM levels, and therefore, 
further studies identifying the exact molecular pathway(s) regulated by pM N-Aβcore is 
essential.  A good starting point would be to perform RNA-sequencing to assess which 
proteins are affected with pM as compared to nM N-Aβcore treatment.     
 Another interesting result was the increase in basal synaptic transmission with the 
treatment of the N-Aβcore.  It would be interesting to assess whether this increase is 
sustained over a long period of time or if it falls back to baseline levels.  Additionally, 
elucidating the underlying mechanism of the N-Aβcore may also speak to this observed 
enhancement.  For example, CREB has been shown to upregulate BDNF, an important 
regulator in synaptic remodeling and cognitive processes [148, 216], and therefore, the 
upregulation of CREB activity and expression in our neuronal model may contribute to 
the synaptic enhancement.  
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 Additionally, more in-depth electrophysiology experiments should be performed to 
address the exact contribution of the NMDA, AMPA and metabotropic glutamate 
receptors in the impact of the N-Aβcore as well as Aβ regulation LTP and LTD induction 
and expression.  In addition to the aforementioned receptors, the role of PrPc should also 
be explored in the neuroprotective action of N-Aβcore on synaptic plasticity.  
 In this study, we did not look at the effects of the N-Aβcore on tau phosphorylation. 
An interesting upstream Ca2+-dependent regulator of tau phosphorylation is calpain.  
Activation of calpain increases the activity of several kinases implicated in 
phosphorylating tau, such as cyclin-dependent kinase 5 (CDK5), glycogen synthase 
kinase β (GSKβ), and MAPK [348].  Thus, assessing the activity of calpain and the 
aforementioned kinases with N-Aβcore treatment would be of interest.   
 Lastly, a more physiological relevant model will need to be studied to substantiate 
our findings.  In addition to our neuronal model, it would be important to confirm the 
molecular pathway regulated by the N-Aβcore in primary hippocampal cultures and/or 
hippocampal slice cultures.  Furthermore, analysis on the hippocampal slices after LTP 
or LTD induction to assess changes in expression of key proteins implicated in synaptic 
plasticity and neuroprotection should be explored.  Overall, these studies will address the 
neuroprotective mechanisms of the N-Aβcore on neuronal survival and synaptic 
modulation.     
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